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ABSTRACT
A CryAB Interactome Reveals Clientele Specificity
and Dysfunction of Mutants Associated
with Human Disease
Whitney Katherine Hoopes
Department of Microbiology and Molecular Biology, BYU
Master of Science
Small Heat Shock Proteins (sHSP) are critical molecular chaperones that function
to maintain protein homeostasis (proteostasis) and prevent the aggregation of other
proteins during cellular stress. Any disruption in the process of proteostasis can lead to
prevalent diseases ranging from cancer and cataract to cardiovascular and Alzheimer’s
disease. CryAB (αB-crystallin, HspB5) is one of ten known human sHSP that is
abundant in the lens, skeletal, and cardiac muscle. This protein is required for cardiac
function and muscle cell integrity. When the cell experiences physiological stress,
including heat shock, CryAB moves to the cytoskeleton to act as a chaperone and
prevent aggregation of its protein clientele. This research is designed to investigate the
molecular role of CryAB in cell proteostasis through the identification of putative
protein clientele and chaperone activity analysis. We have identified over twenty
CryAB-binding partners through combined yeast two-hybrid (Y2H) and co-purification
approaches, including interactions with myofibril proteins. Previously reported diseaseassociated CryAB missense variants were analyzed in comparison to wild type CryAB
through Y2H binding assays. The characterization of the similarities and differences in
binding specificities of these variants provide a foundation to better understand the
chaperone pathways of CryAB and how these changes in molecular function result in
the development of disparate diseases such as cataract, cancer, and various myopathies.

Keywords: small Heat Shock Proteins (sHSP), HspB5 (αB-crystallin, CryAB), molecular
chaperones, proteostasis, R120G, HspB2
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SPECIFIC AIMS
CryAB (αB-crystallin, HspB5) is a small Heat Shock Protein (sHSP) expressed in
various tissues and is critical in maintaining cellular homeostasis. CryAB is one of ten
human sHSP that respond to cellular stress (e.g. heat, cold, oxidative, reductive, etc.)
These chaperones function as anti-apoptotic proteins and help protect the cell from
accumulating protein aggregates. Altered proteostasis is a critical event in the
development of neurodegenerative, cardiac, and other various myopathy diseases
resulting in the formation of protein aggregates. R120G-CryAB is a highly studied
variant that has been shown to be a direct cause of protein misfolding and the growing
accumulation of cytoplasmic aggregates that can lead to the development of
cardiomyopathy. These aggregates propagate the enlargement of the heart, resulting in
physiological changes including preventing efficient heart contraction and the inability
to adequately deliver oxygen throughout the cardiovascular system. A key to
understanding this disease is to elucidate the mechanisms of protein misfolding within
cardiomyocytes. These studies examine the basic pathways involved in proteostasis and
provide a foundation to further understand the molecular pathophysiology of
cardiomyopathy and other associated diseases.
In addition to its expression in cardiomyocytes, the CryAB protein is also a
primary cause of cataract, breast cancer, other myopathies, and Alzheimer’s disease.
Studies that investigate the molecular role of CryAB suggest that this protein functions
as a diverse chaperone to suppress the formation of cytoplasmic aggregates of
particular protein clientele. Although studies have shown this protein to be
multifunctional, little is known why various mutations in CryAB cause such disparate
disease states.
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We hypothesized that CryAB will interact with a diverse variety of human
proteins, including myofibril and regulatory proteins. CryAB has been shown to
localize to the cytoplasm, and upon exposure to stress conditions, translocate to the
cytoskeleton. Our preliminary data indicated that wild type CryAB and R120G-CryAB
chaperones have altered protein-binding clientele, demonstrating a compromised
cardiac protein maintenance environment in the presence of the missense R120G
mutation. These findings suggest that studying the binding clientele of the various
reported CryAB mutants could help explain their functional differences and molecular
dysfunction.

Specific Aim I: Identify novel protein clientele of CryAB through yeast two-hybrid
screening.

Specific Aim II: Contrast the binding affinities of CryAB including wild type,
truncations, and reported disease-causing variants using yeast-two hybrid approaches.
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CHAPTER ONE: CryAB Molecular Chaperone Activity

INTRODUCTION
Protein homeostasis, termed “proteostasis” is a critical process to maintain
optimal cellular health conditions. The pathways of proteostasis require molecular
chaperones to help maintain the central dogma in regulating protein synthesis, protein
folding, and protecting cells from the accumulation of misfolded protein aggregates
both under normal and stressed conditions [1-2]. When cells are subjected to various
forms of physiological stress (e.g. heat shock, ischemia, exercise, etc.), these molecular
chaperones are critical to help the cell maintain proteostasis and maintain the clearance
of unfolded proteins [3-4]. When cells experience such stress, many proteins begin to
denature and form cytoplasmic aggregates. These physiological stress conditions elicit
the role of small heat shock proteins, including CryAB (αB-crystallin, HspB5) to
maintain proteostasis. This introduction will provide information regarding CryAB and
highlight its diverse molecular role as a chaperone to maintain overall cellular and
protein clientele health.

SMALL HEAT SHOCK PROTEINS
There are ten small Heat Shock Proteins (sHSP) that are expressed throughout
the human body (HspB1-HspB10) that prevent the formation of denatured protein
aggregates. These proteins share a highly conserved alpha-crystallin domain and range
in size from 12-43 kDa [3, 5]. Many proteins require molecular chaperones to properly
fold and require the aid of sHSP chaperones to help facilitate this process under
homeostatic conditions. Some molecular chaperones are known to be constitutively
expressed throughout the body while the expression of others are tissue restricted and
3

specifically induced during the exposure of physiological stress conditions. These sHSP
act as the first line of defense and possess chaperone activity to bind to denatured
protein clientele and prevent their aggregation, and function as anti-apoptotic proteins
to protect the cell from accumulating misfolded protein aggregates [6]. These sHSP can
either bind their specific clientele in an ATP-independent process, or transfer denatured
proteins to larger ATP-dependent heat shock proteins to either recover or degrade the
protein clientele [5]. To aid in this process, these chaperones have the ability to form
both homo- and heteromeric structures with other sHSP monomers. The formations of
these complexes allow specific substrate binding, and are regulated by various events
including phosphorylation and hydrophobic associations [7-9]. Interestingly, the
protective role of these molecular chaperones is only elicited by specific interactions
with particular protein-protein interactions. Studies suggest that the oligomers of sHSP
contain multiple substrate binding sites, and therefore, multiple sHSP specific clientele
[10].

THE ALPHA-BETA CRYSTALLIN PROTEIN CRYAB
Protein Features and Expression
CryAB is ubiquitously expressed throughout the body and due to this
characteristic, remains of clinical importance. CryAB is a 175 amino acid protein with a
molecular mass of ~20,159 Da. It is located on human chromosome 11 and uniquely
shares an intergenic promoter with a closely related sHSP, Heat Shock Protein Beta 2
(HspB2), suggesting they share physiological, structural, and regulatory elements [11].
The close proximity of CryAB and HspB2 has interfered with the independent
characterization of these chaperones. These two genes are oriented in a head-to-head
position and are only 958 base pairs apart from transcriptional start sites. Although
4

CryAB and HspB2 share common regulatory elements, the varying levels of expression
within tissues suggest they have unique and separate roles. CryAB expression has been
shown to be induced following heat shock, while HspB2 expression remains unaffected
by this physiological stress [12].
In the process of characterizing these individual chaperone functions, CryAB
knock-out (KO) mice unintentionally removed regulatory elements that were also
required for HspB2 expression, an inadvertent result of their close proximity. Double
KO mice of both CryAB and HspB2 were characterized by lower cardiac respiration
rates, lower ATP, and reduced glutathione levels (a compromised ability to reduce
reactive oxygen species (ROS)) compared to wild type mice [11]. The absence of either
sHSP results in vulnerability of cardiomyocytes to incur severe damage post-ischemia.
To better characterize the specific and unique cardioprotective role of CryAB, the
CryAB gene was transgenically expressed in the double KO mice. The protection of
cardiac diastolic contractile performance was dependent on the expression of CryAB.
HspB2 contributed to the quality of recovery for systolic performance and cardiac
energetics, including ATP recovery [11]. In addition, the unique roles of CryAB and
HspB2 were evaluated through comparing and contrasting their cellular binding
partners. Identification of the HspB2 interactome revealed a role for this chaperone in
mitochondrial function [13].
CryAB is constitutively expressed throughout the body but has been
predominantly known as a structural protein of the lens. This protein is also highly
expressed in tissues with high oxidative capacity including both cardiac and skeletal
muscles [14]. The highest levels of CryAB expression in non-ocular tissue occurs in the
heart, where it can consist of 1-3% total soluble protein [15]. CryAB was first found to
harbor chaperone activity in its ability to suppress the thermally induced aggregation of
5

several enzymes [16]. Specifically within cardiomyocytes, this sHSP functions to protect
cytoskeletal organization and intermediate filament assembly [11, 17]. Heat shock can
increase the expression of CryAB and promote interactions with its protein clientele to
prevent the formation of stress-induced protein aggregation. This sHSP has the
capability to assemble into large oligomers and form multimeric cytosolic complexes
with other sHSP to prevent protein denaturation [18]. The overexpression of CryAB in
mouse hearts, demonstrated the cytoprotective role of this sHSP protecting
cardiomyocytes from ischemic damage [19]. CryAB is a very critical protein in a variety
of tissues, given that several reported mutations have shown diminished chaperone
activity, and therefore, result in pathophysiological development.

Molecular Properties
CryAB expression has been previously localized to the I-bands of myofibrils,
supporting a role of muscle maintenance and stress tolerance [20]. Due to the highly
soluble properties of CryAB, this chaperone remains within the cytosol. Physiological
stressors including heat and ischemia will induce its translocation to the I-band to
facilitate specific interactions with other proteins including actin, desmin and titin [21].
Several heat shock proteins have been reported to interact directly with proteins
involved in apoptosis pathways and interfere with the activation of programmed cell
death function [22]. CryAB has been characterized as an anti-apoptotic protein as it
functions to inhibit initiation of apoptotic pathways. Studies have shown this protein to
inhibit the activation of both the mitochondrial and death receptor pathways.
Interestingly, both of these pathways involve the activation of procaspase-3, suggesting
this chaperone negatively regulates the activation of downstream pathways through the
inhibition of caspase-3 [23].
6

THE R120G-CRYAB VARIANT
It is important to understand the molecular roles of CryAB in maintaining
cellular health and to characterize the mechanisms of action that are affected in reported
CryAB alleles. The exploration of these pathways provides insight to the development
of associated diseases. R120G-CryAB, a highly studied variant of the CryAB protein,
has been shown to induce the development of a life-threatening disease, protein
aggregation cardiomyopathy, in both humans and mice [20, 24-25]. This
pathophysiology is characterized by the upregulation and accumulation of R120GCryAB protein. The R120G-CryAB mutant was first identified as a mutation inherited in
desmin-related myopathies. The R120G mutation is an autosomal dominant mutation
that results in the amino acid change from A → G in CRYAB, a residue that is highly
conserved and required for functional protein structure [20].
Several studies have shown that CryAB variants, including R120G-CryAB,
acquire altered chaperone activity and protein function [26-28]. Using real-time
spectroscopy, the ability of R120G-CryAB to stabilize alpha-lactalbumin was
significantly compromised compared to wild type CryAB, supporting a compromised
chaperone activity [29]. The cardiomyopathy that results from this missense mutation is
due to a toxic gain-of-function property and is dependent on the overexpression and
altered metabolism of glucose-6-phosphate dehydrogenase (G6PD). Analysis of R120G
cardiac tissue revealed protein aggregate formation and the upregulation of G6PD, a
key supplier of NADPH [30]. This upregulation of G6PD is novel to the development of
desmin-related cardiomyopathy, but the precise molecular pathway remains to be
discovered. These changes result in the development of protein aggregates, including
CryAB and protein clientele, and altered redox stasis of cardiomyocytes. Interestingly,

7

the protein aggregation formation has been shown to be reversible when R120G
expression is suppressed [30]. The characterization of CryAB and its role to maintain
structure and reductive homeostasis is necessary to further understand how this
missense mutation interferes with proteostasis.
Several human diseases are characterized by the increased expression of this
mutant chaperone. The specific mechanisms in which this mutant protein contributes to
disease remain to be elucidated. Depending on the location of the mutation, different
variants of CryAB result in different pathologies. Interestingly, HspB1 co-aggregated
with R120G-CryAB in the hearts of myopathic mice. The knockdown of HspB1 resulted
in an increase in protein aggregation of several CryAB mutants, including R120G,
450delA, and 464delCT mutants, suggesting a cytoprotective role of HspB1 in
preventing the accumulation of CryAB protein aggregates [31]. The R120G-CryAB
variant has been shown to be a direct cause of both cataract and cardiomyopathy,
however most other variants of the CryAB protein result in only one phenotype, either
cardiomyopathy or cataract. Each CryAB variant harbors a different mechanism in
which it elicits a specific pathophysiology. R120G-CryAB remains the most extensively
studied variant of CryAB so far, both in protein structure and mechanism of action. This
compromised chaperone activity results in aggregate formation of mutant CryAB and
other clientele proteins including desmin [25].

Phenotypes Associated with R120G-CryAB
Oxidative stress is characteristic to many cardiac diseases including a decrease in
GSH (reduced Glutathione) to GSSG (oxidized Glutathione) ratio. Reductive stress (an
increased GSH to GSSG ratio) may also have negative implications when it comes to
cardiac disease and chaperone function. The overexpression of R120G-CryAB results in
8

cardiac hypertrophy, heart failure and ultimately early onset of death. Several
transgenic mouse lines were created to determine if the R120G-CryAB mutant was a
direct cause of desmin-related myopathy (DRM). In comparison to wild type CryAB,
R120G-CryAB directly led to aberrant CryAB and desmin protein aggregates,
compromising overall cardiac muscle function [25]. Transgenic mice that harbor the
R120G-CryAB mutation had an increase in the reduced form of GSH and interestingly
an increase in Hsp25 expression, a redox-dependent heat shock protein [30]. This study
also found increased levels of glucose-6-phosphate dehydrogenase (G6PD), glutathione
reductase, peroxidase, and catalase in a dose-dependent manner with R120G-CryAB
expression [30, 32]. Increased molecular interactions between CryAB, Hsp25, and G6PD
with heart specific R120G-CryAB expression were also noted. When G6PD-deficient
mice were crossed with R120G-CryAB transgenic mice, no chaperone dysfunction or
consequences occurred, thus providing evidence that the reductive stress was a direct
mechanism of action for R120G-CryAB induced cardiomyopathy [30].
Desmin-related cardiomyopathy is characterized by the formation of
intracellular aggregates containing both CryAB and desmin. Studies have shown that
this mutation results in a dysfunction of cardiac chaperone activity resulting in altered
contractile capabilities and disrupted mitochondrial function [33]. Ultimately this can
lead to an increase in apoptotic activity and overall heart failure. Wild type CryAB
functions to maintain cytoskeletal integrity and protect protein clientele by binding
unfolded proteins and preventing their denaturation and aggregation. A key aspect to
understand these pathophysiologies is to understand the clientele and pathways that
are affected by R120G-CryAB altered chaperone activity.
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OTHER DISEASE-ASSOCIATED ALLELES
Several reports of CryAB mutants have been linked to a variety of human
diseases. These include both skeletal and cardiac myofibrillar myopathies, and cataract.
R120G-CryAB mutant knock-in mice develop cardiomyopathy and cataract similar to
that of humans, defined by the characteristic accumulation of CryAB-desmin aggregates
within the lens and muscle cells [30]. Several other missense CryAB mutants were
identified including R11H, P20S, R56W, D109H, D140N, G154S, R157H, and A171T [3441]. All of these mutations have been reported to contribute to the development of
cataract and/or cardiomyopathy. The anti-apoptotic characteristic of CryAB remains of
high interest in the study of several forms of cancer (e.g. ovarian, breast, etc.) [42-44].
An increase in apoptotic activity has been reported for the R120G, D109H, and A171T
mutants [33, 45]. This data suggest that these mutations disrupt the anti-apoptotic
function of wild type CryAB.
In support of HspB1 function to suppress the formation of protein aggregates
resulting from the R120G variant, another study provided supporting evidence that the
overexpression of HspB1 inhibits the protein aggregation that results as a consequence
of mutated CryAB protein [45]. The mechanisms in which these mutations alter
chaperone activity and protein clientele remains to be elucidated. R157H-CryAB is a
missense mutation found in inheritable Dilated Cardiomyopathy (DCM). This mutation
affects a highly conserved amino acid within the alpha-crystallin family. The resulting
mutation did not affect the cellular distribution of crystallin protein but resulted in a
decreased binding affinity to the titin-connectin heart-specific N2B domain [40]. The
R157H-CryAB variant is better characterized as a loss-of-function mutation in contrast
to the gain-of-function associated with R120G-CryAB.
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CONCLUSION
The cell can experience many physiological stressors that range from myocardial
ischemia to heat shock. The cell responds to stress and initiates critical downstream
pathways to protect protein structure and function. Molecular chaperones, including
sHSP, are key players in these protective processes. The proper protein folding
processes of many cellular proteins require the function of molecular chaperones, and
their ability to promote protein degradation following a physiological stress. During
basal conditions, these molecular chaperones behave in a cytoprotective manner,
however heterogeneous dominant gene mutations can compromise normal chaperone
activity and produce subsequent pathophysiologies.
The results of these aims will provide direct insight to the molecular mechanisms
of CryAB and its chaperone activity of protein interactors. These studies will increase
our knowledge of sHSP function and how disease-causing alleles result in the
dysfunction of their chaperone activity and protein clientele that can ultimately, lead to
the disruption of proteostasis.
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CHAPTER TWO: A CryAB Interactome Reveals Clientele Specificity and
Dysfunction of Mutants Associated with Human Disease
Whitney Hoopes , Nick Nielson , Rachel Farnsworth , Kent Jarvis , John Kauwe , Ivor J.
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ABSTRACT
Small Heat Shock Proteins (sHSP) are molecular chaperones critical in
maintaining proper protein synthesis, function and degradation within cells. The sHSP
CryAB (αB-crystallin, HspB5) has been implicated as an antioxidant protein essential to
maintain proper cytoskeletal organization and myofibril function. More than nine
autosomal dominant and recessive human mutations in CryAB have been associated
with various human diseases including cardiomyopathy and cataract. Despite the clear
importance of CryAB function, the precise molecular pathways and protein clientele are
poorly understood, with few characterized clientele (e.g. BAG family molecular
chaperone regulator 3 and several myofibril proteins including titin, actin, and desmin).
Herein, we provide the first large-scale protein interactome for human CryAB identified
through both yeast two-hybrid (Y2H) and co-purification studies, and report the
identification of several putative myofibril clientele as well as putative clientele
involved in central metabolism. The CryAB interactome is compared with the recently
published interactome of the ohnologous chaperone HspB2, with little (33%) overlap,
suggesting some differences in chaperone function for these sHSP. In addition to the
wild type CryAB interactome, Y2H screens were performed for several disease-causing
variants, allowing comparison of binding partners to identify changes in molecular
function associated with several of the reported missense mutations. This study helps
provide a basis for further work in understanding the novel molecular functions of
CryAB through the identification of putative in vivo clientele. In addition, it provides
methods for analyzing the chaperone dysfunction of CryAB variants to help elucidate
the molecular mechanisms for prevalent diseases.
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INTRODUCTION
Heat Shock Proteins (HSP) are ATP-independent molecular chaperones that help
proteins retain their functional structure, deliver misfolded proteins for degradation,
and prevent partially unfolded proteins from forming cytoplasmic aggregates [1-2].
They are conserved in all cellular organisms where they function in a variety of
essential processes including cell cycle control, apoptosis, autophagy, myogenesis, and
muscle structure maintenance [3-6]. The principal Heat Shock Proteins are divided into
subgroups based on their molecular mass and function. There are ten known Small
Heat Shock Proteins (sHSP) encoded in the human genome that are defined by their
size (15-30 kDa) and the presence of a highly conserved, C-terminal alpha-crystallin
domain [7-8]. Although they have variable expression patterns, they are thought to
share overlapping roles including protein clientele.
CryAB (αB-crystallin, HspB5) is a sHSP that was first known for its structural
role as a lens crystallin and has since been shown to function in cytoskeletal
maintenance, apoptosis, cell cycle regulation, intracellular protein transport, stress and
hormone signaling, Golgi architecture, and immune response (for a recent review see
[9]). CryAB is ubiquitously expressed throughout the human body with the highest
expression in mammalian tissues that are characterized by increased rates of oxidative
metabolism including the heart, skeletal muscle, kidney, brain, and ocular lens [7, 10].
Specifically within cardiomyocytes, CryAB plays a cytoprotective role in maintaining
cytoskeleton remodeling and diastolic contractile performance including cellular redox
state [4, 10]. This role in muscle maintenance is supported by the functional interaction
of CryAB with desmin intermediate filaments [5, 11]. Fitting with its expression
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patterns, several human CryAB alleles have been reported that cause a variety of
protein aggregation diseases including cardiomyopathy and cataract [12-20].
More than nine autosomal dominant and recessive mutations in the CryAB
coding region have been linked to human disease including five that cause cataract
disease, two that cause myofibrillar myopathies, and two variants that result in both
pathophysiologies (see Table 2.4.) [12-20]. Although these CryAB variants have been
reported, the molecular basis for these missense mutations causing a wide variety of
disparate diseases remains to be discovered. The R120G-CryAB variant, named for the
single missense amino acid substitution (Arginine to Glycine at codon 120), is the beststudied variant and is known to cause inheritable protein aggregation cardiomyopathy
through the initiation of oxido-reductive stress [21]. This R120G-induced
cardiomyopathy is due to an increase in glutathione recycling, an overexpression of
glucose-6-phosphate dehydrogenase (G6PD), a key supplier of NADPH, and a related
increase in reduced glutathione [21]. Accordingly, the repression of G6PD
overexpression rescues R120G-mutant mice from the development of this phenotype as
well as the subsequent reductive stress [21]. In support of this antioxidant role, the
R120G mutation enhances the phosphorylation of CryAB during oxidative conditions,
which under homeostatic conditions has been shown to stimulate the translocation of
CryAB to myofibrillar Z-discs to maintain muscle structure and function following heat
shock [9, 11]. The R120G mutant protein also displays greater binding affinity for
desmin and is found in aggresomes that contain both misfolded desmin [22] and a toxic
amyloid oligomer, linking cardiomyopathy-associated chaperone dysfunction to a
variety of neurodegenerative phenotypes including Alzheimer’s disease [23].
Despite its clear importance, the precise molecular pathways of CryAB function
in the heart and skeletal muscle are poorly understood. Only a handful of protein
15

substrates have been characterized for CryAB, including BAG family molecular
chaperone regulator 3 (BAG3), F-actin, titin and desmin [22, 29]. Herein, we provide the
first large-scale protein interactome for CryAB identified through both yeast two-hybrid
(Y2H) screens and co-purification methods and report the identification of twenty-four
binding partners in total, including several myofibril clientele. The CryAB interactome
also provides support for non-redundant sHSP clientele as it is compared to the recently
reported HspB2 interactome [24], in that only a subset of the proteins in the smaller
CryAB interactome overlap with the HspB2 interactome or interact with both CryAB
and HspB2 when directly tested in the Y2H system. In addition to understanding wild
type CryAB function, this interactome provides a basis for identifying the dysfunction
of reported disease alleles, and was used to test the function of eight other variants,
with several displaying altered binding specificity (either gain- or loss-of-function).
Thus, this study not only establishes a basis for identifying the overlapping yet unique
roles of the ten human sHSP, but also allows for the further characterization of CryAB
disease-causing alleles, including R120G-CryAB.

16

MATERIALS AND METHODS
Plasmids, Primers, and Allele Construction
A list of plasmids and primers are provided in Supplementary Table 2.1. & 2.2.
Wild type CryAB was cloned into the Y2H bait plasmid pGBKT7 (Clontech) using
primers JG2609 and JG2461 and standard polymerase chain reaction (PCR)-based
cloning methods. The resulting plasmid of wild type CryAB (pJG736) was used as the
parent plasmid for all subsequent mutant allele and truncation construction. Mutant
alleles were made using Strategene’s QuikChange Lightning Site-directed Mutagenesis
Kit (Agilent Technologies, Santa Clara, CA) and method, with primers outlined in
Supplementary Table 2.2. All plasmids were sequenced (BYU DNA Sequencing Center)
to verify correct truncation and/or base pair change. CryAB truncations and alleles
were cloned into Clontech’s prey (pGADT7) plasmid using standard cloning
techniques. All restriction enzymes were purchased from New England BioLabs (NEB,
Ipswich, MA).

Y2H Screens
Protein clientele for the wild type and R120G-CryAB chaperones were identified
using the Y2H Matchmaker Gold protocol (Clontech). The Y2H Gold yeast strain
(Clontech) expressing R120G-CryAB (pJG581) was mated with yeast expressing either
the Human ORFome cDNA library (Clontech) or Human Cardiac cDNA library
(Clontech). Yeast colonies that grew on the Y2H selection plates (SD-Trp-Leu-His-Ade)
were patched to confirm their phenotype and subjected to colony PCR (using oligos
JG2761 and JG2762) and verified through DNA sequencing (BYU DNA Sequencing
Center) for identification of the library plasmid insert. In total for the R120G Y2H
screens, over 130 million matings were performed with a total of approximately 1,500
17

transformations. Sequences were reported for e-values greater than e . Y2H screens
-50

were performed with the Human Cardiac cDNA library (Clontech) for CryAB variants
outlined in Table 2.4. as previously outlined for R120G-CryAB. To verify positive
protein-protein interactions, the library plasmids were purified from yeast and retransformed into naïve yeast (Y2H Gold, Clontech) harboring R120G-CryAB (pJG581),
wild type CryAB (pJG736) or the empty vector bait plasmids (pJG485, pGBKT7,
Clontech). The resulting yeast colonies were selected on SD-Trp-Leu plates, and
streaked onto SD-Trp-Leu-His-Ade to determine reporter gene expression dependency
with either R120G-CryAB or wild type CryAB. Dependency tests were performed in
triplicate.

Y2H Allele Interactions and Growth Assays
Both CryAB truncations and missense variants expressed in the Y2H bait
pGBKT7 vector were co-transformed into Y2H Gold yeast cells with either ALDOA
(pJG774) or PGM1 (pJG1159), protein clientele identified from the R120G-CryAB Y2H
screen. The resulting yeast colonies were selected on SD-Trp-Leu plates and streaked
onto SD-Trp-Leu-His-Ade to determine interaction strength in comparison to wild type,
R120G-CryAB, and empty vector bait plasmids. For Y2H growth assays, saturated
overnights were grown in SD-Trp-Leu media for 48 hours at 30°C to select for bait and
prey plasmids, followed by a 1:5 serial dilution in water and spotted onto medium
lacking the appropriate amino acids (SD-Trp-Leu-His-Ade) Y2H interaction selection
plates, as well as SD-Trp-Leu control plates to ensure plasmid selection and equal
dilution. Plates were incubated at 30°C for 2-3 days until colonies were apparent.
Growth assays were performed in triplicate.
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Mammalian Heat Shock and Mass Spectrometry
C2C12 mouse myoblast cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) and supplemented with 10% fetal bovine serum (GE Healthcare Life
Sciences). C2C12 cells were plated at 150,000 cells per well and transfected with 1.5 "g
plasmid DNA, 3.5 "l LTX-plus reagent and 5 "l lipofectamine (Invitrogen Life
Technologies) according to standard cell transfection protocol. Transfected plasmids
expressed human CryAB fused to Myc peptide (pJG483) [25] or empty plasmid pCMVMyc vector (pJG906, Clontech). C2C12 myoblast cells were heat shocked 48 hours posttransfection at 45°C for 30 minutes, followed by a 4 hour recovery at 37°C. The cells
were resuspended and lysed in 300 "l mammalian lysis buffer (20 mM HEPES pH 7.8,
10 mM KCl, 100mM NaCl, 1mM EDTA, 1mM EGTA, 1% NP-40, 10% Glycerol, 1mM
DTT, mammalian PICs) and homogenized on ice. The cell lysates were centrifuged for 5
minutes at 13,000 rpm. Both the supernate and pellet were analyzed on 12% SDS-PAGE
and proteins transferred to nitrocellulose blot paper. Myc-tagged CryAB co-purification
samples were prepared for mass spectrometry (MS). MS analysis was performed in
duplicate. Heat shock assays were analyzed on 12% SDS-PAGE, transferred to
nitrocellulose paper, and visualized with appropriate antibodies including anti-ALDOA
(Proteintech Group) and anti-beta Tubulin (Cell Signaling Technologies).
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RESULTS
Selection of CryAB Constructs for Yeast Two-Hybrid Screening
To test the functionality of wild type CryAB in yeast prior to large scale
screening, we constructed various CryAB truncations designed to strengthen or weaken
self-oligomerization based on the findings of Laganowsky et al. [8]. This study reported
the CryAB truncation (aa 68-162) to maintain chaperone activity for target proteins,
while the further truncation of CryAB (aa 68-157) resulted in a loss of chaperone
function [8]. As predicted, the C-terminal truncation from amino acid 164 on
strengthened self-oligomerization as this domain is known to contribute to chaperone
function and oligomerization, while the larger C-terminal truncation from amino acid
160 on weakened it (Figure 2.1. and Table 2.1.). These results suggest that CryAB folds
in a similar manner in yeast cells and can function and self-oligomerize as predicted.

Figure 2.1.
A diagram of CryAB alleles and truncations analyzed in this study to evaluate their
ability to maintain self-oligomerization and chaperone activity. Each truncation is
represented, with the terminal amino acid of that truncation highlighted in red.
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Table 2.1.
Behavior of full-length and truncated CryAB and R120G-CryAB in the yeast two-hybrid
system suggests the constructs of CryAB function similarly to the native protein when
using S. cerevisiae as a model organism. Yeast two-hybrid interactions of various CryAB
truncations were assayed for self-oligomerization. Y2H Gold cells (Clontech) containing
either empty vector, full-length, or truncated forms of CryAB and R120G-CryAB
proteins in both bait and prey plasmid backbones were co-transformed and streaked
onto Y2H selective media (SD-Trp-Leu-His-Ade) to determine interaction strength.
Plates were incubated at 30°C for 3-4 days until growth was apparent. Growth was
scored as weak, moderate, or strong according to colony size.
CryAB Construct

pJG#s

Self-Oligomerization
Strength

Full-length WT CryAB

736/576

Moderate

CryAB aa1-169

577/578

Weak

CryAB aa1-162

1554/1555

Moderate

CryAB aa1-158

580/583

No Growth

Full-length R120G-CryAB

581/1292

Moderate

R120G-CryAB aa1-169

587/588

Moderate/Strong

R120G-CryAB aa1-162

589/590

No Growth

R120G-CryAB aa1-158

584/582

No Growth
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Y2H Screen with CryAB Reveals Expanded Binding Partners for the R120G Variant
The molecular mechanisms of CryAB were explored through the identification of
CryAB clientele in yeast. The initial Y2H screens for CryAB binding partners were
performed with the full-length, wild type CryAB bait (pJG736) and the Clontech
Human Heart cDNA library as prey. However, these screens yielded extremely low
mating rates and efficiencies, making it difficult to identify clientele. Alternatively,
when the R120G-CryAB variant was used as bait (pJG581), yeast mating was restored
and an approximate 1,500 putative interactions were retrieved from over 130 million
matings total with two, independent Y2H libraries. The Human Heart cDNA library
(Clontech) and Human ORFome cDNA library (Clontech) were each used to screen for
putative binding partners. A majority (>90%) of the resulting interactions yielded
CryAB encoded in the prey plasmid as determined by colony PCR with CryAB-specific
forward and prey plasmid-specific reverse primers (JG2461 and JG2762 respectively).
Colonies with prey plasmids not encoding CryAB were sequenced, purified from
yeast, and amplified using E. coli. In order to verify R120G-CryAB protein dependency
as well as to test its interaction with wild type CryAB, each putative binding partner
was reintroduced into naïve yeast containing the Y2H empty vector (pJG485), wild type
CryAB (pJG736), or the R120G-CryAB (pJG581) bait plasmids. The resulting
transformants were streaked onto yeast two-hybrid selective media (SD-Trp-Leu-HisAde) to determine the presence of a protein-protein interaction (see Figure 2.2.). The
eighteen prey plasmids identified from both Y2H libraries in total, that were also
verified to be CryAB or R120G-CryAB dependent are provided in Table 2.2.
The yeast two-hybrid identified unique clientele for R120G-CryAB, including
proteins involved in a variety of cellular processes. A majority of the proteins (~39 %)
localize to the cytoskeleton, consistent with the reported localization of CryAB (see
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Table 2.2. and Figure 2.3.). Several of the protein clientele (~33%) are known to be
involved in muscle structure and regulation, which is consistent with the muscle
maintenance role previously reported for CryAB [10]. In addition to myofibril putative
clientele, we identified several binding partners involved in central metabolic processes
(~17%), including the Fructose-Bisphosphate Aldolase A (ALDOA, pJG774) and
Phosphoglucomutase 1 (PGM1, pG1159).

Figure 2.2.
Comparison of CryAB and R120G-CryAB reveal unique and expanded binding partners
for R120G. Provided are examples of differential clientele binding of the CryAB and
R120G-CryAB proteins via yeast two-hybrid methods. Y2H Gold cells (Clontech) were
co-transformed with bait plasmid (BD, pGBKT7, Clontech) and prey plasmids (AD,
pGADT7, Clontech). Overnights were grown in SD-Trp-Leu for plasmid maintenance,
diluted 5-fold serially, and plated on Y2H selective media (SD-Trp-Leu-His-Ade)
including control plates (SD-Trp-Leu). Plates were incubated at 30°C for 2-3 days until
colonies were apparent.
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Table 2.2.
CryAB binding partners retrieved from yeast two-hybrids screens. R120G-CryAB was
used as bait in yeast two-hybrid screens with two, different prey libraries including a
Human Heart cDNA library (Clontech) and a Human ORFome cDNA library
(Clontech). Proteins encoded by the plasmids retrieved from the Y2H screen are
provided with protein name, UniProt accession #, gene symbol, cellular localization,
and amino acid truncation found in the construct. Only putative clientele that were
verified as positive Y2H interactions are listed. Gene symbols indicated with an asterisk
are R120G-CryAB dependent only and do not interact with wild type CryAB in our
assay.
Uniprot
Accession

Protein Name

Gene
Symbol

Cellular
aa Construct
Localization

Myofibril or Cytoskeleton Structure/Regulation
Microtubule-associated protein 1B

P46821

MAP1B

Cytoskeleton

2114 - 2343

Myomesin-1

P52179

MYOM1

Cytoskeleton

1020 - 1289

Myosin-6

P13533

MYH6

Cytoskeleton

1655 - 1855

Myosin-7

P12883

MYH7

Cytoskeleton

1701 - 1859

Titin

Q8WZ42

TTN

Cytoskeleton

20056 - 20305

Xin actin-binding repeat-containing
protein 1

Q702N8

XIRP1

Cytoskeleton

1629 - 1844

Fermentation/Respiration
Fructose-bisphosphate aldolase A

P04075

ALDOA

Cytoplasm

108 - 365

Cytochrome b

P00156

MT-CYB*

Mito IM

-1 - 263

Phosphoglucomutase 1

P36871

PGM1*

Cytoplasm

177 - 366

Signal Transduction
Macrophage receptor MARCO

Q9UEW3

MARCO

PM

118 - 323

Roundabout homolog 2

Q9HCK4

ROBO2

PM

498 - 744

Gene/Protein Expression
AT-rich interactive domain-containing
protein 2

Q68CP9

ARID2

Nucleus

1351 - 1692

DDB1- and CUL4-associated factor 6

Q58WW2

DCAF6

Nucleus

422 - 627

Histone-lysine N-methyltransferase 2C

Q8NEZ4

KMT2C

Nucleus

2452 - 2790
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Zinc finger protein 177

Q13360

ZNF177

Nucleus

76 - 425

CRYAB

Cytoskeleton

-3 - 175

NBN*

Nucleus

201 - 462

Golgi

-4 - 251

Chaperone
Alpha-crystallin B chain

P02511
Cell Repair

Nibrin

O60934

Intracellular Trafficking
Golgi SNAP receptor complex member 1

O95249

GOSR1

*Abbreviations include Mitochondrial Inner Membrane (Mito IM) and Plasma Membrane (PM).
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A.

B.

Figure 2.3.
Putative binding partners for CryAB revealed by Y2H confirm a role in myofibril
maintenance and suggest roles in metabolism. A) A pie chart of the localization of
putative R120G-CryAB binding partners. B) A pie chart of the reported functions for the
putative R120G-CryAB binding partners.
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There were several proteins isolated from the Y2H screens that were CryAB and
R120G-CryAB dependent, but either out of frame or nonfunctional when verified by
sequence analysis. We propose that CryAB and R120G-CryAB were able to interact with
these clientele, despite being nonfunctional, due to a possibly altered protein structure
as a result of being out of frame (see Supplementary Table 2.3.). Further analysis is
required to explore these interactions and is outside the scope of this study.
As hypothesized from the wild type CryAB and R120G-CryAB Y2H screening
results, we identified an expanded set of protein clientele for the R120G variant when
compared to wild type CryAB. Of the eighteen putative protein clientele identified from
the Y2H screens using R120G-CryAB as bait, three proteins were determined to be
unique binding partners to this variant, consistent with the predicted gain-of-function
associated with R120G [26] (see Table 2.2.), while other clientele revealed differences in
binding affinity/strength interaction between the wild type and variant. These
expanded clientele included Mitochondrially Encoded Cytochome B (MT-CYB),
Phosphoglucomutase 1 (PGM1), and Nibrin (NBN), demonstrating specificity for
R120G-CryAB, and possibly revealing critical proteins that aggregate with this variant
and result in various human disease phenotypes. These results are consistent with
previous hypotheses that due to a novel ability to bind a wider array of proteins, this
variant possibly causes direct aggregation of otherwise partially functional proteins,
disrupting proteostasis and ultimately resulting in disease including cataract and
cardiomyopathy [21, 26-28].
The recently published HspB2 interactome [24] revealed the specificity in which
HspB2 binds its targets by comparing interactions with CryAB and demonstrating
unique clientele for each chaperone. For twelve binding partners isolated from the
HspB2 Y2H screen, wild type CryAB only interacted with four HspB2 clientele (33%)
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[24]. Of these four putative clientele, CryAB and ALDOA were both identified from the
CryAB Y2H screens. Also, the comparison of localization for the putative protein
clientele of both CryAB and HspB2 reveal interesting differences (see Figure 2.4.). For
HspB2, 19% of putative protein clientele localized to the mitochondria, whereas only
~6% for CryAB clientele did. In addition, 7% of HspB2 clientele localized to the nucleus
in comparison to ~28% for CryAB partners. These findings support a role of nonredundant function and specificity in sHSP protein interactions for both CryAB and
HspB2.

Figure 2.4.
Analysis of localization for putative protein clientele for both CryAB and HspB2
support a role of non-redundancy and specificity.
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Co-purification Identifies Additional Putative Binding Partners
Co-purification of overexpressed CryAB in the undifferentiated mouse
myoblasts cell line C2C12, followed by mass spectrometry (MS) of wild type CryAB
(pJG483) [25] identified only six putative protein clientele (see Table 2.3.) Full-length
CryAB fused to Myc was purified in triplicate and subjected to mass spectrometry. The
six reported binding partners were identified only in the CryAB samples and not empty
vector control. Interestingly, Eukaryotic translation elongation factor 1 alpha 1
(EEF1A1), identified from the wild type CryAB MS, was also determined to be a
binding partner of HspB2 via Y2H [24]. However, we could not detect an interaction
between EEF1A1 and CryAB in our Y2H assay. The association of CryAB with EEF1A1
may be through its binding to HspB2, as the advantage of co-purification is that it
isolates large protein complexes
Despite the identification of six putative clientele through co-purification
approaches, we obtained a much lower yield of protein interactions than we expected
for the CryAB interactome. We propose that the pCMV-Myc construct of CryAB results
in the expression of a partially functional protein. Previous use of this plasmid in other
published studies have not directly explored the functionality or chaperone activity of
CryAB in this construct. In support of this prediction, heat shock chaperone assays were
designed to demonstrate the rescue function of CryAB. Using ALDOA as a substrate, a
clientele identified from the Y2H interactome, no difference was observed between
C2C12 cells overexpressing wild type CryAB (pJG483) in comparison to empty vector
(pJG906). Due to the expression of a partially functional CryAB protein, there was no
rescue of ALDOA from aggregating out into the pellet, following a thirty-minute heat
shock (see Figure 2.5.). Troponin was used as a negative control, in which we predict no
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protein-protein interaction, to demonstrate the inability of CryAB to interact and rescue
this protein from aggregating into the pellet.

Table 2.3.
CryAB binding partners identified by co-purification and subsequent mass
spectrometry. Myc-tagged full-length CryAB (pJG483) [25] was purified in triplicate
and analyzed for protein-protein interactions by quantitative mass spectrometry.
Associated proteins were analyzed in both CryAB (pJG483) and empty vector control
(pJG906) independent samples. The reported proteins were present only in the wild
type CryAB samples. Columns indicate the protein name, NCBI accession number, gene
symbol, and number of times retrieved from a total of three samples (none were
retrieved from all three).
Protein Name

NCBI Accession Gene Symbol # Hits

Hypothetical protein

149250554

N/A

2

Chromodomain helicase DNA binding protein 3

124358950

CHD3

1

Caseinolytic protease x isoform 1

113205071

CLPX

1

Eukaryotic translation elongation factor 1 alpha 1

126032329

EEF1A1

1

Eukaryotic translation elongation factor 1 alpha 2

6681273

EEF1A2

1

Annexin A11

7304885

ANXA11

2
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Figure 2.5.
Mammalian construct of CryAB results in a partially functional protein and fails to
rescue the precipitation of identified putative clientele. Overexpression of CryAB fails
to rescue ALDOA from denaturation in mammalian cells following a thirty-minute heat
shock. Lysates were analyzed by 12% SDS-PAGE, transferred to nitrocellulose, and
imaged with anti-ALDOA (Proteintech Group). Anti-beta Tubulin was used as a
loading control (Cell Signaling Technologies).

Analysis of CryAB Mutants Reveals Altered Chaperone Function
As has been previously reported in the literature, mutations in the human CryAB
gene result in distinct, yet disparate phenotypes for each variant including cataract,
muscle, and heart myopathies. Only two variants, D109H and R120G, have been
reported to cause multisystemic disease, which is characterized by multiple pathogenic
phenotypes [15, 20]. Sacconi et al. used molecular modeling to demonstrate that the
mutated amino acids of the D109H variant are involved in self-oligomerization,
suggesting that the impairment of CryAB dimerization is important in its disease
mechanism and may explain the differential phenotype of various mutants [15].
Mutations may also impair clientele binding as is reported by Inagaki et al. for both the
R120G and R157H mutations [18]. In their study, mammalian-two-hybrid assays were
performed by co-transfecting wild type CryAB, R120G and R157H with a plasmid
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containing a specific titin cDNA domain known to associate with CryAB. Decreased
binding was observed in cells expressing either mutant as indicated by a decrease in
luciferase activity [18]. In support of this claim, the 68-162 amino acid truncation of
R157H-CryAB by Laganowsky et al. demonstrated a loss of chaperone activity for target
proteins, while the wild type form of this truncation maintained chaperone binding [8].
To test previously reported disease-associated mutations for alterations in selfoligomerization and/or clientele binding, the wild type CryAB bait plasmid pGBKT7
(Clontech) was mutated to produce nice of the reported variants as outlined in Table
2.4. To test for loss or maintenance of chaperone function, each plasmid construct was
then further sub-cloned into the prey pGADT7 (Clontech) plasmid to test for
oligomerization against itself, as well as one R120G-specific and one shared protein
clientele (PGM1 and ALDOA, respectively).
Interestingly, both the R11H and D140N mutants interfered with selfoligomerization when tested via the yeast two-hybrid system, while none of the other
mutants impaired self-oligomerization (see Table 2.5.). Several of the reported variants
reside in the C-terminal extension that has been shown to house chaperone function,
predicting they abolish chaperone function. Lie et al. characterized the D140N variant
as a dominant negative sHSP through its loss of chaperone activity and reduced
thermal stability, proposing this may be the direct cause of cataract [38]. Our results
support the same loss of chaperone activity demonstrated by its inability to bind wild
type CryAB clientele using the yeast two-hybrid system (see Table 2.7.).
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Table 2.4.
Previously reported CryAB missense mutations and human disease phenotypes. Nine
variants were identified from previously published studies for their role in the
development of cardiomyopathy and cataract and chosen for further study herein. The
mutant, amino acid change, base pair change, pathophysiological phenotype, and study
reference are provided.
Mutant aa Change bp Change

Phenotypes

Study Reference

R11H

Arg →His

G→A

Cataract

Chen et al. 2009

P20S

Pro → Ser

C→T

Cataract

Liu et al. 2006

R56W

Arg → Trp

C→T

Cataract

Safieh et al. 2009

D109H

Asp → His

G→C

Cardiomyopathy & Cataract Sacconi et al. 2011

R120G

Arg → Gly

A→G

Cardiomyopathy & Cataract Vicart et al. 1998

D140N

Asp → Asn

G→A

Cataract

G154S

Gly → Ser

G→A

Cardiomyopathy

Pilotto et al. 2006

R157H

Arg → His

G→A

Cardiomyopathy

Inagaki et al. 2006

A171T

Ala → Thr

G→A

Cataract

Liu et al. 2006

Devi et al. 2008

In studies performed by Lie et al., the D140N mutation did not appear to be
involved in self-interaction even though it’s located in the same ACD region as D109H
and R120G. Instead, the D140N missense mutation results in a loss of chaperone
activity, in support of our Y2H findings, indicated by its inability to prevent the
aggregation of insulin in vitro. In addition, this variant was also found to be more
susceptible to heat denaturation and resulted in the formation of larger oligomers than
wild type CryAB, altering both the tertiary and quaternary structure of alpha-crystallin
[38].
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Table 2.5.
Yeast two-hybrid self-oligomerization assays for wild type CryAB and nine reported
CryAB alleles. Changes in self-oligomerization were analyzed using the Y2H system for
nine reported CryAB variants. Y2H Gold cells (Clontech) containing either empty
vector, full-length or CryAB alleles in both bait and prey constructs were cotransformed and streaked onto Y2H selective media (SD-Trp-Leu-His-Ade) to
determine interaction strength and/or altered binding affinity. Plates were incubated at
30°C for 3-4 days until growth was apparent.
CryAB Construct

pJG#s

Strength

Full-length WT CryAB

736/576

Moderate/Strong

R11H-CryAB

1337/1339

No Growth/Weak

P20S-CryAB

1269/1585

Moderate/Strong

R56W-CryAB

1268/1293

Moderate/Strong

D109H-CryAB

1280/1295

Moderate/Strong

R120G-CryAB

581/1292

Moderate/Strong

D140N-CryAB

1296/1526

Very Weak

G154S-CryAB

1363/1364

Moderate

R157H-CryAB

1307/1308

Moderate/Strong

A171T-CryAB

1602/--

--

In contrast to self-oligomerization, several mutants displayed altered putative
binding of CryAB clientele. While wild type CryAB was able to interact with ALDOA
indicated by a weak/moderate binding affinity via Y2H, all other variants except R120G
and P20S were unable to interact with this putative clientele suggesting a loss of wild
type function. Interestingly, PGM1 was identified as a unique substrate for the R120G
variant. P20S was the only variant that was able to weakly interact with this clientele,
whereas the other variants behaved similarly to wild type for this particular clientele.
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This may suggest that P20S-CryAB also acts through a gain-of-function mechanism
similar to R120G.

Table 2.6.
Binding partners identified from the CryAB interactome are compared to CryAB
truncations. Comparison of CryAB truncations using the yeast two-hybrid system to
test for clientele binding of PGM1 and ALDOA revealed altered binding protein and
interaction strengths. Y2H Gold cells (Clontech) containing either empty vector or
CryAB (including full-length and truncations) were transformed and streaked onto Y2H
selective media (SD-Trp-Leu-His-Ade) to determine interaction strength and/or altered
binding affinity. Plates were incubated at 30°C for 3-4 days until growth was apparent.
Y2H Bait CryAB
Construct

pJG#

Interaction Strength with
PGM1 (pJG1159)

Interaction Strength with
ALDOA (pJG774)

Full-length WT CryAB

736

No Growth

Weak/Moderate

CryAB aa1-169

577

No Growth

No Growth

CryAB aa1-162

1554

No Growth

No Growth

CryAB aa1-158

583

Weak/Moderate

Moderate

Full-length R120G-CryAB

581

Moderate/Strong

Moderate/Strong

R120G-CryAB aa1-169

587

Moderate/Strong

Weak/Moderate

R120G-CryAB aa1-162

589

No Growth

No Growth

R120G-CryAB aa1-158

584

Strong

Moderate/Strong
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Table 2.7.
Binding partners identified from the CryAB interactome are compared to other reported
CryAB variants. Comparison of CryAB variants using the yeast two-hybrid system to
test for clientele binding of PGM1 and ALDOA revealed altered binding protein and
interaction strengths. Y2H Gold cells (Clontech) containing either empty vector or
CryAB (including full-length and alleles) were transformed and streaked onto Y2H
selective media (SD-Trp-Leu-His-Ade) to determine interaction strength and/or altered
binding affinity. Plates were incubated at 30°C for 3-4 days until growth was apparent.
Y2H Bait CryAB
Construct

pJG#

Interaction Strength with
PGM1 (pJG1159)

Interaction Strength with
ALDOA (pJG774)

Wild type CryAB

736

No Growth

Weak/Moderate

R120G-CryAB

581

Moderate/Strong

Moderate/Strong

R11H-CryAB

1337

No Growth

No Growth

P20S-CryAB

1269

Very Weak

Moderate/Strong

R56W-CryAB

1268

No Growth

No Growth

D109H-CryAB

1280

No Growth

No Growth/Weak

D140N-CryAB

1296

--

No Growth

G154S-CryAB

1363

No Growth

Very Weak/Weak

R157H-CryAB

1307

No Growth

No Growth/Weak

A171T-CryAB

1602

--

--
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Using the Yeast Two-Hybrid to Detect Dysfunction of Human CryAB Variants
Given the altered binding affinities for CryAB and R120G clientele among other
reported variants, Y2H screens were initiated using the human cardiac cDNA library
(Clontech). Screens are in progress for P20S (pJG1269), D109H (pJG1280), R157H
(pJG1307), R11H (pJG1337), and G154S (pJG1363). Preliminary screen transformation
results show several of these variants to have an extremely low mating efficiency,
similar to that of wild type CryAB. Other variants seem to behave more similar to that
of R120G-CryAB, as indicated by similarities in Y2H mating efficiencies. These Y2H
screens will provide valuable insight into the behavior of each mutant chaperone and
may reveal unique putative clientele as was revealed for the R120G mutant.

DISCUSSION
sHSP have many important implications in maintaining proteostasis. Their roles
in a variety of human diseases demonstrate the need to explore the pathways and
interactions sHSP have within the cell. This study uses the powerful and highly
sensitive Y2H method to detect protein-protein interactions of CryAB and the highly
studied variant R120G. Our study provides the first reported protein interactome for
wild type CryAB and R120G-CryAB. In support of the putative gain-of-function
characteristic attributed to R120G-CryAB, this variant had an expanded clientele when
compared to the wild type protein. Specific clientele in this expanded interactome may
be useful in studying the unique pathways in which R120G causes disease.
Co-purification studies for the wild type protein revealed poor results with only
six putative clientele. Interestingly, one of these clientele (EEF1A1) was also identified
as a putative clientele in the HspB2 interactome [24]. The same construct used for the
co-purification analysis of wild type CryAB was used to perform heat shock assays and
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explore the chaperone function of this protein with putative clientele identified from the
Y2H. In support of the poor results of the CryAB co-purification studies, this protein
was unable to rescue clientele after C2C12 cells overexpressing CryAB were subjected to
heat shock. We propose that this construct of CryAB protein may have decreased
function and is unable to test chaperone function in vivo.
Using the CryAB protein interactome provided in this study, reported CryAB
variants were tested for altered chaperone function in Y2H assays with CryAB and
R120G clientele as well as for self-oligomerization. Interestingly, these assays revealed
similarities to either wild type CryAB or R120G, suggesting gain-of-function
mechanisms for other variants such as P20S. Y2H screens were initiated and will
provide a basis for identifying critical interacting proteins involved in disease
phenotypes associated with each variant. CryAB is a multifunctional protein involved
in several critical cellular pathways. Exploring the gain and/or loss of protein-protein
interactions for each variant will provide insight into the chaperone activity of each
CryAB variant.
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Supplementary Table 2.1.
Plasmid
Selection Expression Reference
Backbone

Plasmid Gene Description
pJG483

CryAB WT fused to Myc

pJG485

N/A

pJG549

N/A

pGBKT7 Y2H bait from Clontech
Y2H Gold system
pGADT7 Y2H prey from Clontech
Y2H Gold system

pCMVMyc

Amp

Mammalian

[25]

pGBKT7

Kan/Trp

Yeast

Clontech

pGADT7

Amp/Leu

Yeast

Clontech

pJG576

CryAB Full-length WT CryAB

pGADT7

Amp/Leu

Yeast

This study

pJG577

CryAB WT CryAB (aa1-169)

pGBKT7

Kan/Trp

Yeast

This study

pJG578

CryAB WT CryAB (aa1-169)

pGADT7

Amp/Leu

Yeast

This study

pJG580

CryAB WT CryAB (aa1-158)

pGADT7

Amp/Leu

Yeast

This study

pJG581

CryAB Full-length R120G-CryAB

pGBKT7

Kan/Trp

Yeast

This study

pJG582

CryAB R120G CryAB (aa1-158)

pGADT7

Amp/Leu

Yeast

This study

pJG583

CryAB WT CryAB (aa1-158)

pGBKT7

Kan/Trp

Yeast

This study

pJG584

CryAB R120G CryAB (aa1-158)

pGADT7

Kan/Trp

Yeast

This study

pJG585

CryAB WT CryAB (aa1-169)

pGBKT7

Kan/Trp

Yeast

This study

pJG586

CryAB WT CryAB (aa1-169)

pGADT7

Amp/Leu

Yeast

This study

pJG587

CryAB R120G CryAB (aa1-169)

pGBKT7

Kan/Trp

Yeast

This study

pJG588

CryAB R120G CryAB (aa1-169)

pGADT7

Amp/Leu

Yeast

This study

pJG589

CryAB R120G CryAB (aa 1-162)

pGBKT7

Kan/Trp

Yeast

This study

pJG590

CryAB R120G CryAB (aa 1-162)

pGADT7

Amp/Leu

Yeast

This study

pJG736

CryAB Full-length WT CryAB

pGBKT7

Kan/Trp

Yeast

This study

pJG773 MYOM1 Retrieved from R120G Y2H Screen

pGADT7

Amp/Leu

Yeast

This study

pJG774 ALDOA Retrieved from R120G Y2H Screen

pGADT7

Amp/Leu

Yeast

This study

pJG776

pGADT7

Amp/Leu

Yeast

This study

CRYAB Retrieved from R120G Y2H Screen

pJG786

XIRP1

Retrieved from R120G Y2H Screen

pGADT7

Amp/Leu

Yeast

This study

pJG784

MYH6 Retrieved from R120G Y2H Screen

pGADT7

Amp/Leu

Yeast

This study

pJG805

MTCYB Retrieved from R120G Y2H Screen

pGADT7

Amp/Leu

Yeast

This study

pJG825

MYH7 Retrieved from R120G Y2H Screen

pGADT7

Amp/Leu

Yeast

This study

pJG826 MARCO Retrieved from R120G Y2H Screen

pGADT7

Amp/Leu

Yeast

This study

pJG828

Retrieved from R120G Y2H Screen

pGADT7

Amp/Leu

Yeast

This study

MAP1B Retrieved from R120G Y2H Screen

pGADT7

Amp/Leu

Yeast

This study

pCMVMyc

Amp

Mammalian

Clontech

pGADT7

Amp/Leu

Yeast

This study

pJG836
pJG906

TTN

N/A

pCMV-myc-N Empty Vector

pJG1155 ROBO2 Retrieved from R120G Y2H Screen
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pJG1157 DCAF6 Retrieved from R120G Y2H Screen

pGADT7

Amp/Leu

Yeast

This study

pJG1159

Retrieved from R120G Y2H Screen

pGADT7

Amp/Leu

Yeast

This study

pJG1160 GOSR1 Retrieved from R120G Y2H Screen

pGADT7

Amp/Leu

Yeast

This study

pJG1221

Retrieved from R120G Y2H Screen

pGADT7

Amp/Leu

Yeast

This study

pJG1222 KMT2C Retrieved from R120G Y2H Screen

pGADT7

Amp/Leu

Yeast

This study

pJG1224

ARID2 Retrieved from R120G Y2H Screen

pGADT7

Amp/Leu

Yeast

This study

pJG1225 ZNF177 Retrieved from R120G Y2H Screen

pGADT7

Amp/Leu

Yeast

This study

pJG1268

CryAB R56W-CryAB

pGBKT7

Kan/Trp

Yeast

This study

pJG1293

CryAB R56W-CryAB

pGADT7

Amp/Leu

Yeast

This study

pJG1269

CryAB P20S-CryAB

pGBKT7

Kan/Trp

Yeast

This study

pJG1280

CryAB D109H-CryAB

pGBKT7

Kan/Trp

Yeast

This study

pJG1292

CryAB R120G-CryAB

pGADT7

Amp/Leu

Yeast

This study

pJG1295

CryAB D109H-CryAB

pGADT7

Amp/Leu

Yeast

This study

pJG1296

CryAB D140N-CryAB

pGBKT7

Kan/Trp

Yeast

This study

pJG1307

CryAB R157H-CryAB

pGBKT7

Kan/Trp

Yeast

This study

pJG1308

CryAB R157H-CryAB

pGADT7

Amp/Leu

Yeast

This study

pJG1337

CryAB R11H-CryAB

pGBKT7

Kan/Trp

Yeast

This study

pJG1339

CryAB R11H-CryAB

pGADT7

Amp/Leu

Yeast

This study

pJG1363

CryAB G154S-CryAB

pGBKT7

Kan/Trp

Yeast

This study

pJG1364

CryAB G154S-CryAB

pGADT7

Amp/Leu

Yeast

This study

pJG1526

CryAB D140N-CryAB

pGADT7

Amp/Leu

Yeast

This study

pJG1554

CryAB WT CryAB (aa1-162)

pGBKT7

Kan/Trp

Yeast

This study

pJG1555

CryAB WT CryAB (aa1-162)

pGADT7

Amp/Leu

Yeast

This study

pJG1585

CryAB P20S-CryAB

pGADT7

Amp/Leu

Yeast

This study

pJG1602

CryAB A171T-CryAB

pGBKT7

Kan/Trp

Yeast

This study

PGM1

NBN
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Supplementary Table 2.2.
Primer Description

Sequence

JG2461 CryAB forward (full-length) GGCGAATTCGACATCGCCATCCACCACCCC
JG2603 CryAB reverse (at aa158)

GGCGTCGACCTAGGTGCGCTCAGGGCCAGAG

JG2604 CryAB reverse (at aa169)

GGCGTCGACCTAGACAGCAGGCTTCTCTTCACG

JG2606 CryAB reverse (at aa162)

GGCGTCGACCTAACGGGTGATGGGAATGGTGC

JG2609 CryAB reverse (full-length)

GGCGTCGACCTATTTCTTGGGGGCTGCGGTGAC

JG2761 pGADT7 libary insert (PCR) CTATTCGATGATGAAGATACCCCACC
JG2762 pGADT7 libary insert (PCR) AGATGGTGCACGATGCACAG
JG2860

pGADT7 libary insert
(sequencing)

CAGAGGTTACATGGCCAAGATTG

JG2877

pGADT7 libary insert
(sequencing)

CTATTCGATGATGAAGATACCCCACCAAACCC

JG3157 CryAB forward (full-length) CCGCATATGGACATCGCCATCCACCACCCC
JG3158 CryAB reverse (full-length)

GCCGGATCCCTATTTCTTGGGGGCTGCGGTGAC

JG3538

CryAB R157H for
mutagenesis

GGTCTCTGGCCCTGAGCACACCATTCCCATCACCCG

JG3539

CryAB R157H for
mutagenesis

CGGGTGATGGGAATGGTGTGCTCAGGGCCAGAGACC

JG3540

CryAB G154S for
mutagenesis

CCAAGGAAACAGGTCTCTTCCCCTGAGCGCACCATTCC

JG3541

CryAB G154S for
mutagenesis

GGAATGGTGCGCTCAGGGGAAGAGACCTGTTTCCTTGG

JG3543 CryAB P20S for mutagenesis CTTTCCTTTCCACTCCACCAGCCGCCTCTTTGACC
JG3544 CryAB P20S for mutagenesis GGTCAAAGAGGCGGCTGGTGGAGTGGAAAGGAAAG
JG3545

CryAB R56W for
mutagenesis

GCCACCCTCCTTCCTGTGGGCACCCAGCTGGTTTG

JG3546

CryAB R56W for
mutagenesis

CAAACCAGCTGGGTGCCCACAGGAAGGAGGGTGGC

JG3594

CryAB D109H for
mutagenesis

CATGAAGAGCGCCAGCATGAACATGGTTTCATCTCC

JG3595

CryAB D109H for
mutagenesis

GGAGATGAAACCATGTTCATGCTGGCGCTCTTCATG

JG3596

CryAB R11H for
mutagenesis

CCACCACCCCTGGATCCACCGCCCCTTCTTTCCTTTCC

JG3597

CryAB R11H for
mutagenesis

GGAAAGGAAAGAAGGGGCGGTGGATCCAGGGGTGGTGG

JG3598

CryAB D140N for
mutagenesis

CTTCATCCCTGTCATCTAATGGGTCCTCACTGTG

JG3599 CryAB D140N for

CACAGTGAGGACCCATTAGATGACAGGGATGAAG
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mutagenesis
CryAB A171T for
JG3992 mutagenesis

GGCGCGGCCGCCTATTTCTTGGGGGCTGCGGTGAC

CryAB A171T for
JG3993 mutagenesis

GAAGCCTGCTGTCACCACAGCCCCCAAGAAATAG

Supplementary Table 2.3.
Protein Name

Uniprot
Gene Symbol
Accession

Cellular
Localization

Function

HCLS1-associated protein X-1

O00165

HAX1

Cytoplasm

Myofibril or Cytoskeleton
Structure/Regulation

Protein NipSnap homolog 2

O75323

GBAS

Cell Membrane

Small Molecule Biosynthesis

Ferritin light chain

P02792

FTL

Cytoplasm

Iron and Copper
Homeostasis

P00414

MTCO3

Mito IM

Fermentation and Respiration

P43115

PTGER3

Cell Membrane

Signal Transduction

Periostin

Q15063

POSTN

Extracellular

Cell Adhesion

DnaJ homolog subfamily B
member 6

O75190

DNAJB6

Cytoplasm

Chaperone

Integrator complex subunit 8

Q75QN2

INTS8

Nucleus

Replication

Protein kish-A

Q8TBQ9

TMEM167A

Golgi Body

Intracellular Trafficking

ANKRD20A12P

Cytoplasm

Unknown

LINC00927

Not Applicable

Unknown

LINC00943

Not Applicable

Unknown

Cytochrome c oxidase
subunit 3
Prostaglandin E2 receptor
EP3 subtype

Ankyrin Repeat Domain 20
Family, Member A12
Long intergenic non-protein
coding RNA 927
Long intergenic non-protein
coding RNA 943

Noncoding
RNA
Noncoding
RNA
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CHAPTER THREE: Summary and Discussion of Findings
The knowledge provided by these studies will be foundational to understanding
the basic pathways and molecular function of small Heat Shock Proteins (sHSP). Their
contributions to the regulation and structure of cardiac muscle are critical to
maintaining proteostasis. These small molecular chaperones are unique in their ability
to form heteroligomeric complexes and prevent misfolded proteins from forming
cytoplasmic aggregates. Their ability to refold proteins and prevent their denaturation
enables protein clientele to remain functional within the cell. It has been suggested that
sHSP protein interaction is non-specific and redundant in function, with sHSP
interacting with any unstable protein. This idea was supported by the proposed theory
of gene devolution by duplication, in the case of CryAB and HspB2 due to their sharing
of promoter and regulatory transcription elements. However, the conservation of both
sHSP throughout mammals suggests evolutionary selection, and hence some
independent function. This function may be due to differential specificity for substrates,
or alternative expression, localization, regulation, etc. Thus, an in depth study of these
related sHSP may provide evidence for or against the non-specific nature of sHSP.
Both CryAB and HspB2 are expressed predominantly in skeletal and cardiac
muscle, however CryAB is expressed ubiquitously. The chaperone role of CryAB is of
clear importance due to over nine reported dominant and recessive human mutations
resulting in a wide variety of severe, human disease-associated alleles. CryAB has been
highly studied, with the aberrant mutation R120G-CryAB being of primary focus due to
its direct cause of multisystemic disease. Interestingly, studies have not pursued the
characterization of in vivo CryAB clientele. We have recently published the interactome
of HspB2, suggesting over a hundred clientele. This research is the first study aimed to
investigate and characterize the protein clientele and chaperone activity of CryAB,
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which was compared to HspB2 to provide evidence for the differential function of
CryAB and HspB2 at the molecular level. In addition, the CryAB interactome allowed
us to characterize several CryAB alleles associated with human mutation including
R120G-CryAB. Thus, this research also supports a mechanism for the dysfunction of
R120G-CryAB and other reported disease-causing alleles at the molecular level, which
may guide future research in understanding the mechanisms of such disparate diseases.
The binding partners of CryAB identified via yeast two-hybrid shared roles in
muscle maintenance and central metabolism. In response to physiological stress, CryAB
has been shown to bind the cytoskeletal structure and modulate remodeling of the
cytoskeletal network through direct interactions with desmin, actin and titin. CryAB
has been found to play a key role in the development of several disparate human
diseases as a direct result in over nine reported autosomal dominant and recessive
variants. This study provides evidence for the differential binding of wild type CryAB
when compared to various disease-causing alleles. R120G-CryAB remains the most
studied sHSP variants it its contributions to the development of cardiomyopathy and
cataract, replicated both in human and mice studies. The yeast two-hybrid analysis
provided herein identified three binding partners that demonstrated binding specificity
for R120G-CryAB in comparison to the wild type chaperone. This supports a hypothesis
of chaperone dysfunction of R120G binding to otherwise fully functional proteins and
forming aggregates throughout the cell and “gaining” a larger span of protein clientele
in comparison to wild type.
Using the protein clientele retrieved via yeast two-hybrid screening for CryAB
and R120G-CryAB, changes in chaperone activity were characterized for other missense
alleles of CryAB. Yeast two-hybrid analysis reveals changes in self-oligomerization as
well as changes in protein clientele for disease-reported variants. The R120G mutant
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protein has been shown to have reduced chaperone activity under heat stress conditions
which results in increased aggregate formation. This hyper-binding activity may be the
change in chaperone function that results in disease. This chaperone model provides the
basis for studying other missense CryAB mutants and to characterize the change in
chaperone activity for other reported alleles. Changes in ability to bind to wild type
clientele as well as self-oligomerization are the beginning steps to understand the
changes in sHSP activity. This protein-interaction analysis can help to elucidate the
change in molecular mechanisms associated with different disease-causing alleles.
The unique protein clientele of each sHSP, including CryAB, is a novel approach
to reveal the key pathways and molecular function of these chaperones. The yeast twohybrid interactome comparison provided herein for CryAB and HspB2 demonstrate
that even these closely related sHSPs share non-redundant molecular roles and harbor
specificity in their protein-protein interactions. In addition, a different subset of clientele
for R120G-CryAB and several other disease-causing mutants was revealed, containing
both shared and chaperone-specific interaction when assessed via yeast two-hybrid.
This study is the first analysis to identify protein clientele specificity and altered
binding ability for such reported variants. The interactome of CryAB not only provides
insight for the molecular involvement of CryAB in specific metabolic and cardiac
maintenance pathways, but also serves as a basis for studying all reported alleles for
CryAB and their change in mechanisms of action. This research provides a foundation
to identify key pathways critical to the maintenance of cardiac muscle structure and
function.
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APPENDIX A: Characterization of the Cardiac Overexpression of HSPB2 Reveals
Mitochondrial and Myogenic Roles Supported by a Cardiac HspB2 Interactome
CONTRIBUTIONS
In addition to my contributions to the CryAB interactome, I also contributed to
the following study on the related protein chaperone HspB2. My contributions to this
publication included the following:

Table 2: Dependency test transformations for the HspB2 Y2H screen and sequence
analysis of HspB2 protein clientele to determine truncations within library plasmid
constructs.

Table 3: Performed and verified Y2H assay data to demonstrate non-redundancy in
HspB2 vs. CryAB protein clientele.

Figure 6: Created the HspB2 interactome network for all dependent HspB2 Y2H
putative clientele.

Figure 7C: Performed in vivo heat shock assays to provide evidence for GAPDH as a
putative binding partner for HspB2, identified in the Y2H screen.
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Abstract
Small Heat Shock Proteins (sHSPs) are molecular chaperones that transiently interact with
other proteins, thereby assisting with quality control of proper protein folding and/or degradation. They are also recruited to protect cells from a variety of stresses in response to
extreme heat, heavy metals, and oxidative-reductive stress. Although ten human sHSPs
have been identified, their likely diverse biological functions remain an enigma in health and
disease, and much less is known about non-redundant roles in selective cells and tissues.
Herein, we set out to comprehensively characterize the cardiac-restricted Heat Shock Protein B-2 (HspB2), which exhibited ischemic cardioprotection in transgenic overexpressing
mice including reduced infarct size and maintenance of ATP levels. Global yeast two-hybrid
analysis using HspB2 (bait) and a human cardiac library (prey) coupled with co-immunoprecipitation studies for mitochondrial target validation revealed the first HspB2 “cardiac interactome” to contain many myofibril and mitochondrial-binding partners consistent with the
overexpression phenotype. This interactome has been submitted to the Biological General
Repository for Interaction Datasets (BioGRID). A related sHSP chaperone HspB5 had only
partially overlapping binding partners, supporting specificity of the interactome as well as
non-redundant roles reported for these sHSPs. Evidence that the cardiac yeast two-hybrid
HspB2 interactome targets resident mitochondrial client proteins is consistent with the role
of HspB2 in maintaining ATP levels and suggests new chaperone-dependent functions for
metabolic homeostasis. One of the HspB2 targets, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), has reported roles in HspB2 associated phenotypes including cardiac
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ATP production, mitochondrial function, and apoptosis, and was validated as a potential client protein of HspB2 through chaperone assays. From the clientele and phenotypes identified herein, it is tempting to speculate that small molecule activators of HspB2 might be
deployed to mitigate mitochondrial related diseases such as cardiomyopathy and neurodegenerative disease.

Introduction
Studies of molecular chaperones and their regulatory pathways are among the most challenging and illuminating ones for understanding the hierarchical integration among genotype-phenotype relationships, biological systems and cellular networks [1–3]. Among their multifaceted
functions, molecular chaperones transiently interact with other proteins to facilitate protein
folding, translocation, and degradation, all of which contribute to the quality control requirements for maintaining homeostasis of the proteome (termed “proteostasis”). In parallel, systems biology has emerged as a powerful organizing principle for integrating biophysical
properties, creating biological functions of complex webs of macromolecular interactions
(termed the “interactome” network). How molecular (HSP) chaperones might be inextricably
linked to interactome networks and interrelated organelles in cardiac health and disease remain
poorly defined.
In recent decades, attempts to understand genotype-phenotype relationships have been significantly aided by the characterization of inheritable Mendelian traits and experimental
genetic maneuvers such as transgenesis and gene targeting in model organisms. In the present
context, owing to the head-to-tail genomic organization of the genes encoding HspB2 (also
known as Myotonic Dystrophy Protein Kinase Binding Protein, MKBP [4]) and HspB5 (also
known as alpha-B crystallin, CryAB), Brady and collaborators had originally set out to create
the single HSPB5 knockout but inadvertently eliminated both genes resulting in double knockout (DKO) mice [5]. Because DKO mice survived into adulthood, these initial studies were the
first to illustrate that both HSPB2 and HSPB5 deficiency was dispensable for early and postnatal development with relative mild effects of cardiac hypertrophy (~10% heart weight) in adult
hearts, perhaps due to redundancy among sHSPs [5, 6].
Further characterization of DKO hearts by Morrison et al. (2004) revealed severely diminished levels of total reduced glutathione (GSH, 56%) and increased oxidized glutathione
(GSSG) when compared with wild type (WT) mice, suggesting that DKO hearts are under
higher levels of oxidative stress. Evidence of sHSPs in redox state regulation is based on our
earlier work that showed that knockout of heat shock transcription factor 1 (HSF1) in mice not
only lowered basal levels of HspB5 expression but also decreased GSH content [7]. Whereas
HSPB5 deficiency could contribute to the lower GSH in the DKO mice, these findings could
not exclude a role for HspB2, which not only interacts with the outer membrane of mitochondria [8] but has been hypothesized to regulate mitochondria energetics [9]. Taken together,
these studies support the general notion that genotype-phenotype relationships are governed
by higher order complexities, which, in part, are related to variable expressivity, genetic modifiers, incomplete penetrance, redundancy, and age-related conditions.
In an attempt to unmask tissue-specific roles of HspB2, which can be hidden by overlapping
sHSP function, we report here on the phenotypes of cardiac HSPB2 overexpression (OE) as
well as a large-scale cardiac HspB2 protein interactome. HspB2 OE mice (HSPB2cTg) protected cells from ischemia/reperfusion (I/R) and enhanced mitochondrial recovery with
improved ATP levels at reperfusion. These results were supported by a cardiac protein

PLOS ONE | DOI:10.1371/journal.pone.0133994 October 14, 2015

2 / 31

Cardiac Overexpression and Interactome of HspB2

interactome for HspB2 achieved through Y2H and co-immunoprecipitation (co-IP)
approaches. A combined total of 149 HspB2 binding partners are reported, many of which are
mitochondrial. This interacome showed specificity for HspB2 in that HspB5 binds only a subset of HspB2 binding partners. The HspB2 interactome was further supported by preliminary
validation of an HspB2 target, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an
in vivo client. Many of these newly discovered HspB2 binding partners are linked to myopathies or neurodegenerative disease, suggesting a role for HspB2 in these debilitating human
conditions.

Materials and Methods
HSPB2cTg mouse line and controls
Human cDNA of HSPB2 was amplified and inserted under the control of the α-myosin heavy
chain (α-MHC) (Fig 1A) [10]. Transgenic [11] mice were generated by microinjection of fertilized embryos and maintained in a mixed genetic background of the C57Bl/6J and 129S6
strains. Genotyping of the HSPB2cTg mice was performed by PCR using the following primers:
forward AGGCAGGGAAGTGGTGGTGTAGG and reverse GGCCTTCTCCGAAGCGCTGC, respectively. Mice
overexpressing cardiac HSPB2 are referred to as HSPB2cTg and their corresponding Flox wild
type control littermates as HSPB2NTg, whereas the cardiac HSPB2 KO and littermate control
are HSPB2cKO and HSPB2wt, respectively.

Western blot analysis of heart tissue
Mouse hearts were removed and rinsed with ice cold PBS as previously described from our laboratory [9]. The tissue was minced into small pieces and homogenized in 0.25 ml of 50 mM
Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100. Following incubation on ice
for 30 m, the lysates were clarified by centrifugation at 12,000 rpm for 10 m at 4°C. The supernatants were used as detergent-soluble fractions. The resulting pellet fractions were washed
twice and sonicated in 100 μl 1× SDS buffer (50 mM Tris–HCl, pH 6.8, 2% SDS, 100 mM DTT,
10% Glycerol) for 30 s as detergent-insoluble fractions. Protein concentration was determined
and western blots were performed using anti-sHSP (HspB1, HspB2, HspB5, HspB6 and
HspB8) with anti-histone3 and anti-GAPDH as loading controls as previously described [9].
All antibodies were commercially available as described [9], with the exception of the HspB2
antibody which we purchased through 21st Century Biochemicals using the following peptide
sequence: CPATAEYEFANPSRLGEQ-amide. In addition, anti-HspB3 antibodies were
obtained from StressMarq Biosciences Inc. and HspB3 levels were determined on a separate
western blot.

Ischemia reperfusion in vivo
Age-matched male mice (10–12 week-old) selected for the study were bred according to
approved guidelines of Institutional Animal Care and Use Committee (IACUC) at the University of Utah. Animals were anesthetized with a ketamine (100mg/kg) and xylazine (0.5mg/kg)
cocktail administered intraperitoneally. Following tracheal intubation of the trachea, the
mouse was placed on a small rodent ventilator at a respiratory rate of 120 breaths per m and
0.25 ml tidal volume. To maintain temperature control, animals were placed on a water-heated
surgical bed (E-Z Anesthesia, US State) with temperature setting at 37°C. Under sterile conditions, the heart was exposed through the 4th intercostal space and a 7–0 suture, attached to a
balloon, was applied around left descending coronary artery [12]. The cardiac ischemia was
introduced by inflating the balloon while using continuous electrocardiographic (ECG)
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Fig 1. Generation of HSPB2 cardiac specific overexpressors and effects on sHSP expression in transgenic mice (HSPB2cTg). (A) A schematic
diagram illustrates the human heat shock protein B2 (HSPB2) under the control of the α-myosin heavy chain (α-MyHC) promoter: the 3 black boxes in the
promoter represent noncoding exons in the 5’-untranslated region [10] and polyA splicing is provided by the human growth hormone sequences downstream
of the inserted cDNA (hGH). (B) Representative Western blots of cardiac samples of transgenic (HSPB2cTg) mice and non-transgenic (HSPB2NTg)
littermates (n = 4 animals per group) prepared as detergent soluble (supernatant) and non-soluble (pellet) portions, respectively. Protein levels of HSPB2
expression is markedly elevated (~4 x fold) in the HSPB2cTg hearts compared with non-transgenic (HSPB2NTg) littermates when assessed by western blot
using anti-HspB2 antibodies [9]. Representative small heat shock proteins (sHSPs—HspB1, HspB3, HspB5, HspB6 and HspB8) exhibit similar levels in
detergent soluble extracts, while HspB6 is significantly elevated in detergent insoluble fractions. Protein concentration was determined and western blots
were performed using anti-sHSP (HspB1, HspB2, HspB5, HspB6 and HspB8) with anti-histone3 and anti-GAPDH as loading controls as previously
described [9]. In addition, anti-HSPB3 antibodies were obtained from StressMarq Biosciences Inc and HspB3 levels were determined separately, which is
indicated by a black line. (C) Densitometry-based quantification of the levels of protein in the immunoblots in Fig 1B. * P<0.05 when compared with
corresponding HSPB2NTg group.
doi:10.1371/journal.pone.0133994.g001
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monitoring. Myocardial ischemia was monitored by the appearance of pale color of the lateral
myocardial wall to the apex, S-T segment elevation, widening of the QRS, and/or ventricular
arrhythmias on continuous ECG. The duration of ischemia lasted 45 m before the balloon was
deflated and suture tie removed to initiate reperfusion. The chest cavity was closed before extubation of the animal.

Assessment of infarction size
Twenty-four hours (h) after reperfusion start, the mice were euthanized, the hearts were
excised and cannulated with a 20-gauge needle through the aorta, and then the hearts were perfused with Krebs-Henseleit solution [13]. The LAD was sutured and tied at the site of previous
occlusion to permit perfusion of the aorta with 5% Evans Blue, which stains the non-risk area
dark blue. The hearts were trimmed to leave only the left ventricle, which was frozen and sliced
into 6–7 pieces. Staining in a 1% solution of 2,3,5-triphenyltetrazolium chloride (TTC) at 37°C
for 30 m resulted in viable tissue and infarct tissue appearing in red and white colors, respectively. Each piece of heart was photographed (Dino-Lite) on both sides and images were processed with ImagePro Plus 7.0 software. The infarction mass of each piece was calculated as
white (infarcted) average of both sides, divided by the sum of red plus white [14] average of
both sides, then multiplied by the mass of that piece. Total infarction was calculated by the
sum of the mass of infarction divided by the sum of the mass of risk as previously described
from our laboratory [13].

Troponin I measurement
Mouse blood samples were set for clotting before centrifugation for 15 m at 800g. The serum
was collected, diluted in series from 1:10 to 1:1000, and then loaded into a 96-well sample plate
from the High Sensitive Mouse Cardiac Troponin-I kit (Life Diagnostics, Inc.). Troponin I
level was measured at 450 nm by following the manufacturers recommendations.

Mitochondria swelling assay
Mitochondria were isolated from mouse hearts as previously described [9] and diluted to 250
ug/ml in mitochondria swelling buffer containing 120 mM KCl, 10 mM Tris, 5 mM KH2PO4.
The mitochondria were equilibrated for 5 m at room temperature and 250 uM CaCl2 was
loaded to induce swelling. Data was read at 540 nm.

Bioenergetics consequences
For isolated heart studies and 31P NMR data collection, mice were heparizined (50 U/10 g, i.p.)
and anesthetized (ketamine, 80 mg/kg, plus xylazine, 12 mg/kg, i.p.). Excised hearts were retrogradely perfused (60 mm Hg) with modified Krebs–Henseleit buffer (118.5 mM NaCl, 4.7 mM
KCl, 1.5 mM CaCl2,1.2 mMMgSO4 and 1.2 mMKH2PO4) equilibrated with 95% O2/5% CO2,
at 37°C, and containing 0.4 mM palmitate/fatty acid free albumin complex (3:1 molar ratio)
and 10 mM glucose [15]. A water-filled latex balloon was placed into the left ventricle and set
to a diastolic pressure of 5 mm Hg to provide a physiological load.
The isolated perfused hearts were placed inside a 10 mm broadband NMR radiofrequency
probe within a 14.1 T NMR magnet (Bruker Biospin, Billerica, MA) for collection of sequential,
31
P NMR spectra. 31P NMR data provided detection of high-energy phosphate content, including phosphocreatine (PCr) and ATP throughout an I/R protocol. Following collection of
baseline, pre-ischemic baseline NMR data, perfused hearts were subjected to 16 m of global
ischemia at 37°C, followed by 32 m of reperfusion. Relative ATP content in each heart during
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the pre-ischemic, ischemic, and reperfusion periods was determined from the signal intensity
of the β-phosphate resonance signal at -16 ppm. Time-averaged spectra were collected at 243
MHz from the intact beating hearts in 4 m time blocks using 64 scans with a 45° flip angle and
2 s interpulse interval, using previously described data collection and processing/analysis
schemes for high-energy phosphate levels and intracellular pH [15–17].

Y2H screen and HspB2 dependency tests
Yeast harboring a human cardiac cDNA Y2H library (Clontech) were mated by the standard
Matchmaker mating protocol (Clontech) to yeast harboring a full-length human HSPB2 plasmid (pJG591). The bait plasmid (pJG591) was constructed by standard cloning techniques in
which HSPB2 was amplified by PCR from a human template using primers GGCGAATTCT
CGGGCCGCTCAGTGCCAC and GGCGGATCCTCAGGGCTCAACTATGGCTGCC and
cloned into the EcoR1/BamHI sites of pGBKT7 (Clontech) for fusion to the Gal4 DNA binding
domain at the N-terminus; the C-terminus is native. Over 22 million yeasts were mated, from
which 10,000 colonies arose on SD-Trp-Leu plus Aureobasidin (Clontech) selection plates.
Colonies were then patched to alternate Y2H selection plates (SD-Trp-Leu-His-Ade) for phenotype validation through alternate transcriptional reporters (HIS and ADE). The plasmid
inserts of the library were identified for over 1,000 colonies arising on the SD-Trp-Leu-HisAde plates by colony PCR (primer AGATGGTGCACGATGCACAG and CTATTCGATGATGAAGATACCCCA
CC) followed by sequencing and NCBI BLASTN [18] analysis. A subset of library plasmids were
purified and secondarily subjected to false positive analysis. Briefly, plasmids were retransformed into yeast harboring the HSPB2-bait plasmid or empty bait plasmid, selected on
SD-Trp-Leu and streaked to SD-Trp-Leu-His-Ade to test for an HSPB2-dependent interaction.
For HspB2 specificity testing, HSPB5 was PCR amplified from a human template and cloned
into the EcoRI/SalI sites of pGBKT7 (Clontech) using primers GGCGAATTCGACATCGCCA
TC CACCACCCC and GGCGTCGACCTATTTCTTGGGGGCTGCGGTGAC. The HSPB5
bait plasmid was then co-transformed with a library plasmid into yeast, selected on SD-TrpLeu and streaked to SD-Trp-Leu-His-Ade to test for an HSPB5-dependent interaction.

Mitochondrial co-IP proteomics
Mitochondrial HspB2 was immunopurified from mice harboring either the wild type HSPB2
(HSPB2wt), transgenic cardiac HSPB2 (HSPB2cTg), or an HSPB2 cardiac knockout
(HSPB2cKO, [9]). For each group, mitochondria from four mouse hearts were combined,
lysed in 0.1% NP-40 homogenization buffer, and 2 mg was incubated with anti-HspB2 antibodies [9]. The IP eluates were then fractionated on SDS-PAGE, excised and analyzed by
LC-MS/MS. Samples had one biological replicate and two technical replicates. Technical replicates showed greater than 90% overlap. The raw data were analyzed by BioWorks (ThermoFisher Scientific, version 3.3.1 SP1) and proteins were identified using SEQUEST
(ThermoFisher Scientific, version 3.3.1) and Scaffold (Proteome Software, version 3.3.3). At
least two peptides and 99.0% protein confidence were required for protein algorithms; the
global false discovery rate was approximately 0.1%.

Bioinformatic analysis of the HspB2 interactome
Cytoscape version 3.2.1 [19] was used to construct protein-protein interaction networks by
retrieving previously identified interactions from the mentha, Reactome-Fls, Reactome, IntAct
and MINT databases (partners reported for either human or mouse proteins) and mapping
them into a single merged network. Gene Ontology analysis for the resulting networks was
done using the Cytoscape ClueGO plugin [20]. Associated diseases were obtained using the
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Online Mendelian Inheritance in Man (OMIM) database (McKusick-Nathans Institute of
Genetic Medicine, Johns Hopkins University (Baltimore, MD). World Wide Web URL: http://
omim.org/).

Protein purification and in vitro chaperone assays
GAPDH and HSPB2 were cloned into pet15b (Novagen) for expression and purification.
GAPDH was amplified from Origene plasmids SC118869 (accession number NM_002046)
using the following primers, GGCCATATGGGGAAGGTGAAGGTCGGAGTC and GGCGG
ATCCTTACTCCTTGGAGGCCATGTGGGC, and cloned into pet15b at the NdeI/BamHI
sites. HSPB2 was PCR amplified from pJG591 (using primers GGCCATATGTCGGGCCGCT
CAGTGCC and GGCGGATCCTCAGGGCTCAACTATGGCTGCC) and cloned into pet15b
at the NdeI/BamHI sites. Expression vectors were transformed into BL21 (DE3) E. coli (Novagen). Overnight cultures of transformants were diluted 1:500 into LB-AMP and grown for 3 h
at 37°C. Expression was induced by 0.5 mM ITPG for 5 h at 37°C. Pelleted bacteria were then
resuspended in 20 mL XWA lysis buffer (20 mM HEPES pH 7.4, 10 mM KCl, 1.5 mM MgCl2,
1 mM EDTA pH 8.0, 1 mM EGTA, 300 mM NaCl, 1 mM beta-mercaptoethanol, pH 7.4, and
Roche Complete Protease Inhibitor Cocktail). Cells were lysed using the Microfluidics M-110P
homogenizer and debris pelleted at 15,000 rpm for 60 m. The supernatants were incubated
with 250 μL of Ni-NTA agarose (Qiagen) for 2–3 h, beads were washed twice with 15–25 mL of
XWA lysis buffer and then transferred to a column to be washed with 50 mL of lysis buffer containing 25 mM imidazole. Protein was eluted three times per sample with 0.3 mL of lysis buffer
containing 250 mM imidazole and only 100 mM NaCl. The control, porcine citrate synthase
was purchased from Sigma-Aldrich. Proteins were dialyzed into 40 mM HEPES-KOH buffer
(pH 7.5) prior to in vitro chaperone assays. In vitro chaperone assays were conducted as previously described [21] by incubating 0.015 mM GAPDH with and without 0.105 mM HspB2 at
high temperature (43°C) for 30 m in 40 mM HEPES-KOH buffer (pH 7.5). Seven-fold excess
of chaperone compared to substrate is used because oligomerization is required for activity.
Aggregates were then pelleted by centrifugation (13,000 rpm for 10 m in a microcentrifuge).
For chaperone assays, both supernatant and pellet were analyzed by SDS-PAGE. Bands of the
SDS-PAGE gel were analyzed using ImageJ software [22], and pellet to supernatant ratios calculated. Samples were run in triplicate and averaged.

In vivo chaperone assays
In vivo GAPDH chaperone activity assays were performed by transfecting plasmids bearing
human HspB2 fused to myc peptide or the empty plasmid control (pCMV-myc) into C2C12
cells in a 6-well plate using 6.5 μL lipofectamine 2000 (Life Technologies) and manufacturers
protocol. After 48 h at 37°C, cells were shifted to 45°C for 30 m and then placed back at 37°C
for three h prior to lysis. Cells were resuspended in 300 μL lysis buffer (20 mM HEPES (pH
7.8), 10 mM KCl, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40 and 10% glycerol),
homogenized in a Dounce homogenizer ten times for five seconds on ice, and debris pelleted at
13,000 rpm for 5 m. The pellet was resuspended in 100 μL of 2X SDS buffer (125 mM Tris-Cl,
pH 6.8, 0.01% (w/v) bromophenol blue, 100 mM fresh dithiothreitol, 2.5% (w/v) SDS, 25%
glycerol) while 6X SDS buffer was added to the supernatant for a final concentration of 1X.
Samples were boiled 2 m, analyzed by 12% SDS-PAGE and transferred to nitrocellulose paper.
Proteins were visualized using anti-GAPDH antibody, anti-beta-Tubulin antibody, and antiMyc antibody (all antibodies are from Cell Signaling Technologies). Protein bands were analyzed using ImageJ software [22] and pellet to supernatant ratios were calculated.
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Data analysis, statistics and repository
Data are expressed as average ± standard deviation with student's t-test used for statistical analysis using two-tailed distribution and two-sample equal/unequal variance for all experiments
with the exception of the NMR experiments, which were analyzed by ANOVA with StudentNewman Keuls post test [23]. Statistical significance was set at p<0.05. The HspB2 interactome
described herein has been deposited in the Biological General Repository for Interaction Datasets (BioGrid, [24]) where it may be identified by PubMed ID.

Ethics statement
This study was carried out in strict accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Utah (Permit Number:
10–05006). All surgery was performed under ketamine and xylazine cocktail anesthesia administered intraperitoneally, and all efforts were made to minimize suffering.

Results
Cardiac HSPB2 OE does not alter levels of other sHSPs
Cardiac-specific HSPB2 overexpressor mice (HSPB2cTg) were generated using human HSPB2
under the control of α-myosin heavy chain (α-MyHC) promoter as schematically shown in Fig
1A. Neither early lethality nor age-related cardiomyopathy was observed in these HSPB2cTg
mice (data not shown). In detergent soluble extracts, protein levels of HSPB2 were markedly
elevated (~4 fold) in hearts of HSPB2cTg mice (n = 4 animals per group) compared with nontransgenic littermates (HSPB2NTg) (Fig 1B, quantification in Fig 1C). To determine the effects
of HSPB2cTg OE, the expression patterns of several other sHSPs were analyzed by western
blot. The previously reported sHSP binding partners of HspB2 are HspB3 [25, 26], HspB5 [27]
and HspB8 [28]. Protein levels of HspB1, HspB3, HspB5, HspB6 and HspB8 were all found to
be unaltered in the soluble fractions, whereas HspB6 was modestly (P = 0.035) and HspB8 was
non-statistically significantly elevated (P = 0.064) in the detergent insoluble fraction, respectively (Fig 1B and 1C). In contrast, protein levels of HspB1, HspB3 and HspB5 were unaffected
by cardiac-specific HSPB2 OE in intact mouse hearts.

HSPB2 OE protects mouse hearts from I/R injury
We have reported paradoxical effects of either HSPB2 KO and/or HSPB2/HSPB5 DKO in I/R
studies [13, 29]. To investigate the specific role of HSPB2 in I/R injury, transgenic mice overexpressing cardiac HSPB2 (HSPB2cTg) were compared with cardiac HSPB2 KO mice
(HSPB2cKO) and their littermate controls (HSPB2NTg and HSPB2wt respectively, n = 9–11
per group). Mouse hearts of HSPB2cTg (n = 11), HSPB2cKO (n = 9) and their corresponding
controls underwent 45 m of ischemia followed by 24 h of reperfusion in situ. The size of infarction in each mouse heart was analyzed as described in Materials and Methods. An infarction
area of 35.4 ± 5.6% was significantly lower in HSPB2cTg mouse hearts compared with the
infarction area of 48.7 ± 10.0% for the HSPB2NTg controls (p< 0.0006, Fig 2A and 2B). Both
HSPB2cKO and the corresponding Flox control animals (HSPB2wt) developed similar sizes of
heart infarction upon I/R in situ, 49.4 ± 12.1% vs. 48.8 ± 13.5% respectively. Of all cardiac
markers, cardiac specific troponin-I is the most sensitive indicator for cardiomyocyte injury,
and its amount in the blood correlates well with heart infarction size after microvascular
obstruction [30]. In agreement with the smaller cardiac infarction size, HSPB2cTg animals had
significantly lower troponin-I levels after I/R stress compared with HSPB2NTg controls (Fig
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Fig 2. HSPB2 OE protects mouse hearts from ischemia/reperfusion (I/R) injury in vivo. (A)
Quantification of mouse cardiac infarction/risk size 24 h post I/R surgery. Each circle represents one animal
from the transgenic cardiac overexpressor (HSPB2cTg), the cardiac knockout (HSPB2cKO), or control
groups (HSPB2NTg and HSPB2wt, respectively). The number of animals in each group is labeled in the
figure. (B) Representative staining images of mouse cardiac infarction post I/R surgery indicating the
decreased infarct size in HSPB2cTg animals compared to controls. The same groups of animals as A are
shown. Non-risk, live, and infarction tissue stained dark blue, red and white respectively. I/R surgery and
infarction size measurements were performed as described in Material and Methods. The duration of
ischemia lasted 45 m before deflation of the balloon and suture tie to initiate reperfusion. Hearts were excised
24 h after reperfusion start, cannulized, and the aorta was perfused with 5% Evans Blue, which stained the
non-risk area dark blue. (C) Cardiac specific troponin-I levels in mouse serum 24 h post I/R surgery indicate
HSPB2 OE is cardioprotective. Mouse serum was diluted in series from 1:10 to 1:1000, and loaded into a
96-well sample plate from the High Sensitive Mouse Cardiac Troponin-I kit (Life Diagnostics, Inc.). Troponin I
level was measured at 450 nm by following the manufacturers recommendations. * P<0.05 when compared
with corresponding HSPB2NTg group.
doi:10.1371/journal.pone.0133994.g002

2C). Troponin-I levels were similar between HSPB2cTg and HSPB2NTg after sham surgery in
these animals.
In addition to infarct size, the cardiac function of these animals was assessed with both
echocardiography and left ventricle catheter (Table 1). Interestingly, echocardiographic studies
revealed wall motion abnormality at 24-h time points post I/R in HSPB2NTg but not in
HSPB2cTg animals, in support of smaller infarction size in the HSPB2cTg animals. In addition,
cardiac ejection fraction appeared to be reduced only in the HSPB2NTg group, although the
data did not achieve statistical significance. The hemodynamic data acquired by left ventricle
catheter did not show any difference among groups.

Mitochondria function in HSPB2cTg mouse heart with I/R injury
We previously reported a deficit in the recovery of phosphocreatine (PCr) and ATP levels in
the HSPB2-deficient mice following I/R stress, suggesting HspB2 protects mitochondrial function during I/R [9]. The ability of HSPB2 OE to protect ATP synthesis was formally determined
throughout the I/R protocol for each experimental group (HSPB2cTg, n = 7, HSPB2NTg,
n = 5, HSPB2cKO, n = 7, and HSPB2wt, n = 6). Fig 3A–3C displays representative changes in
NMR-detected high-energy phosphate compounds and comparisons of ATP content among
Table 1. Heart function in HSPB2cTg mouse with ischemia/reperfusion injury in vivo. Hemodynamic data is acquired by left ventricle catheter and analyzed by LabChart 7. Echocardiography is acquired with VisualSonics Vevo2100 imaging system. LV, left ventricle; SP, systolic pressure; DP, diastolic pressure; EDP, end diastolic pressure; HR, heart rate; LVEF, left ventricle ejection fraction; IR, ischemia/reperfusion. Each experiment group acquired by LV
catheter contains at least 6 mice. Statistics and calculation of +dp/dt, -dp/dt and LVEF are described in Materials and Methods.
Groups

Sham

I/R

HSPB2NTg

HSPB2cTg

HSPB2NTg

HSBP2cTg

LV catheter
Aorta SP

88.57 ± 23.28

76.41 ± 13.03

73.85 ± 6.38

72.35 ± 6.57

Aorta DP

61.90 ± 11.84

49.25 ± 20.21

50.43 ± 8.53

48.94 ± 9.36

LV SP

89.56 ± 19.61

78.74 ± 12.74

76.79 ± 6.12 *

72.89 ± 5.75

LV EDP

1.96 ± 2.17

2.15 ± 1.75

5.89 ± 2.61

4.97 ± 2.52

HR

328.37 ± 45.02

347.14 ± 39.60

335.02 ± 44.87

345.13 ± 59.35

+dp/dt

5834.53 ± 1650.23

6159.39 ± 2848.88

5196.99 ± 606.56

4785.15 ± 1140.38

-dp/dt

-4867.77 ± 1716.10

-5475.04 ± 1873.88

-4169.81 ± 565.11

-4220.02 ± 1011.12

LVEF

0.700342461

0.78

0.66 ± 0.15

0.81 ± 0.12

Wall motion abnormality

0/1

0/1

3/8

0/4

Echo

doi:10.1371/journal.pone.0133994.t001

PLOS ONE | DOI:10.1371/journal.pone.0133994 October 14, 2015

10 / 31

Cardiac Overexpression and Interactome of HspB2

PLOS ONE | DOI:10.1371/journal.pone.0133994 October 14, 2015

11 / 31

Cardiac Overexpression and Interactome of HspB2

Fig 3. Mitochondrial protection in HSPB2cTg mouse heart with ischemia/reperfusion (I/R) injury. (A)
Representative 31P NMR spectra of a transgenic HSPB2 overexpressor (HSPB2cTg) heart taken at baseline
before ischemia, at 14 m of ischemia, and at 32 m of reperfusion. Phosphocreatine (PCr) was depleted during
ischemia but rapidly recovered upon reperfusion in all groups. Note loss and recovery of ATP content, as
represented by the only resonance that is uncontaminated from signal from ADP and AMP, which is the βphosphate group at -16 ppm. The peak at 3.5 ppm is signal from the intracellular inorganic phosphate (Pi),
which shifts to lower values due to the increasing concentration of diprotonated Pi versus mono-protonated Pi
as the pH becomes increasingly acidic during ischemia. The peak at 5 ppm is a combined signal from both
extracellular pH and residual buffer surrounding and in the isolated perfused heart, which also contains
inorganic phosphate and reflects neutral pH. (B) ATP content after 14 m of ischemia was reduced similarly in
all groups, as shown as a percentage of pre-ischemic content at 100%. (C) Recovery of ATP content upon
reperfusion was greater in HSPB2cTg hearts than in the knockout hearts (HSPB2KO) or control groups
(HSPB2NTg or HSPB2wt, respectively). Values shown are at 2 min reperfusion and did not change
significantly from these over the remaining duration of the reperfusion period. * P<0.05 when compared with
corresponding HSPB2NTg group.
doi:10.1371/journal.pone.0133994.g003

groups at the end of ischemia and upon reperfusion. Although no difference in PCr content
occurred among experimental heart groups at any time throughout the protocol, consistent
with the role of PCr as a phosphagen that responds to reoxygenation of viable mitochondria
following non-lethal ischemia, we did observe a difference in ATP content in the HSPB2cTg
mice.
As shown in Fig 3B, there was no significant difference in ATP loss during the ischemic
period, demonstrating that all groups held similar susceptibility to impaired energy production
during zero flow ischemia. Since oxidative mitochondrial energy production was essentially
shut down during ischemia, the presence or absence of HSPB2 did not affect ATP levels during
ischemia. ATP depletion was required to support the same energy demands for residual cell
function during the ischemic insult among all experimental groups. The similar levels of ATP
hydrolysis (ATP + H2O ! ADP + Pi + H+) that occurred during ischemia among all groups is
consistent with the similar reduction in intracellular pH among the groups, from a preischemic
baseline of 7.1 to the final pH range observed at the end of ischemia of 6.2–6.1. The peak at
3.5 ppm is signal from the intracellular inorganic phosphate (Pi), which shifts to lower values
due to the increasing concentration of diprotonated Pi versus mono-protonated Pi as the pH
becomes increasingly acidic during ischemia. The peak at 5 ppm is a combined signal from
both extracellular pH and residual buffer surrounding and in the isolated perfused heart, which
also contains inorganic phosphate and reflects neutral pH.
In contrast to the similarities observed during ischemia, ATP content and recovery was augmented in HSPB2cTg hearts upon early reperfusion in comparison to all other groups (Fig 3C,
ANOVA with Student-Newman Keuls post test). These data show a 41% to 57% increase in
the postischemic mean ATP content of the HSP2cTg hearts over the other groups. The initial
ATP content seen upon reperfusion persisted throughout the entire assay period in all groups,
with no significant change over time (Repeated Measures ANOVA). These results strongly
support a role for HSPB2 alone via cardioprotection during ischemia and sustained mitochondrial function upon reperfusion.
Kadono et al. suggests that the lack of HSPB2 and HSPB5 preconditions myocytes for damage due to increased calcium sequestration by the mitochondria, a known step in the inducement of mitochondria permeability transition [31, 32]. Mitochondrial swelling assays were
performed in the HSPB2cTg and HSPB2NTg mice to determine if this calcium response is
dependent on HspB2. Although mitochondria isolated from HSPB2cTg hearts (n = 4) trended
toward lower levels of swelling in response to calcium, the differences were not significant
when analyzed by student’s t-test (S1 Fig).
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An unbiased Y2H screen for HspB2 substrates reveals surprising
specificity for mitochondrial binding partners
The foregoing findings for HspB2-associated phenotypes predicts protective roles for HspB2
activators and strongly suggest that HspB2 has hitherto unknown molecular clientele critical to
mitochondrial health, however mitochondrial HspB2 clientele are unreported. To identify
these client proteins, we performed an unbiased, large-scale Y2H screen using a human heart
cDNA Y2H library (Clontech) as prey and human HSPB2 as bait. From over 22 million mated
yeasts, approximately 10,000 putative interactions were detected indicating only one of every
~2,000 mattings resulted in a positive Y2H interaction, suggesting a high degree of specificity
of HSPB2 targets. Over 1,000 library plasmids were re-plated for phenotypic verification and
subsequently sequenced to identify the compendium of interacting partners. As expected for a
molecular chaperone, such sequencing revealed a large number of interacting partners (437
unique hits). These binding partners were further grouped by their frequencies, depending on
if they were retrieved only once (S1 Table, “single-hit” list) or multiple times (Table 2, “multihit” list) in the Y2H screen.
The advantage of high sensitivity in the Y2H method comes at the expense of specificity
(i.e., high false positive rates) [12, 33, 34]. To test the overall reliability of the Y2H, a subset of
the putative binding partners were tested for HSPB2-dependence. Briefly, prey plasmids encoding 90 of the putative HspB2 binding partners (49 from the multi-hit list and 41 from the single-hit list) were purified from yeast and reintroduced into naïve yeast harboring either the
empty bait plasmid or the HSPB2 bait plasmid. A remarkable 81.6% of the 49 multi-hit library
plasmids tested showed a positive Y2H result that was dependent on HSPB2 (i.e., growth with
only the HSPB2 bait, not the empty bait plasmid), 10.2% were false positives (i.e., growth either
with or without HspB2), and 8.2% were true negatives (i.e., no growth with either HspB2 or the
empty bait plasmid). In contrast, we found that only 51.2% of the 41 single hit plasmids harbored HspB2 dependent-binding partners, 12.2% were false positives, and another 36.6% were
true negatives. The multi-hit binding partners with an 82% rate for validation were then
sequenced to determine frame, and are used for all subsequent studies and analysis due to its
reliability.

The Y2H screen identifies non-redundant client proteins of cytosolic
HspB2 and HspB5
In order to test the specificity of the HspB2 Y2H interactome, the interactome was compared
to the recently published HspB1 (Hsp27) interactome in which 228 binding partners were
identified by Katsogiannou et al. from large-scale Y2H screens of testis and Hela cancer cell
libraries [35]. Of the 84 proteins on the high confidence multi-hit HspB2 Y2H list, only two
were identified as HspB1 binding partners (EIF4A2 and GARS), suggesting specificity of the
HspB2 and HspB1 interactomes. However, different Y2H libraries were used in these studies
that could also account for the variances. To further verify specificity of HspB2, a subset of
HspB2 binding partners were tested for their ability to interact with a more closely related
HSP, HspB5 (Fig 4A, Table 3). Remarkably, HspB2 was specific for a majority of the binding
partners tested (eight of the 12 binding partners, or 67%), with only four displaying both
HspB2 and HspB5 binding (including HspB5 itself, which was used as a positive control). In
addition, two of these four HspB2 and HspB5 binding partners gave a much stronger Y2H
result with HspB2 than HspB5. These findings validate the specificity of HspB2 in the largescale Y2H screen and provide further in vivo support for non-redundant clientele among
sHSPs, consistent with expression and phenotypic analyses that have revealed unique functions
for HspB5 and HspB2 chaperones [6].
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Table 2. Putative HspB2 binding partners retrieved from the Y2H screen reveal a role in muscle and mitochondrial maintenance. Proteins retrieved
multiple times from a Y2H screen for HspB2 binding partners (84 hits) are given along with the following information: protein name, UniProt [73, 74] protein
accession number (hyperlink), gene symbol, primary cellular localization reported on HPRD [76] or UniProt, the number of times it was retrieved from the
screen (# hits) and the amino acids corresponding to the library construct from the n-terminal amino acid to the c-terminal amino acid (if the terminal amino
acid is not reached the total amino acids are given in parenthesis). In some cases the nucleotide fusion occurred before the initiating ATG and is indicated by
the number of amino acids upstream of the start (for example, -12–136 for LGALS1 denotes 22 amino acids upstream of the ATG start to amino acid 136).
Hits that did not correspond to a coding sequence are not listed and include the 3’ region of ABLIM1, AXIN1, DYRK1A, FHL1, GPX3, HIPK2, NCAM1,
PPAPDC3, PLXNA4, LRP10, SCN1B, SEC62, SGSM2, SLC25A4, SNTA1, SYNPO, TNIP1, USP28, and XIRP1 mRNA. The proteins are functionally categorized by their description on UniProt [73, 74] and/or GeneCards [73]. See supplementary S1 Table for a complete list of putative HspB2 binding partners
retrieved from the Y2H screen only once.
Protein Name

UniProt Accession

Gene Symbol

Cellular Localization**

# hits

aa

Myoﬁbril or Cytoskeleton Structure/Regulation
Actin, alpha 1, skeletal muscle*

P68133

ACTA1

Cytoskeleton

8

253–377

Actin, beta

P60709

ACTB

Cytoskeleton

2

267–375

Actin, alpha, cardiac muscle 1

P68032

ACTC1

Cytoskeleton

37

84–377

Actin, gamma 1

P63261

ACTG1

Cytoskeleton

5

195–375

Capping protein (actin ﬁlament) muscle Z-line, alpha 2

P47755

CAPZA2

Cytoskeleton

3

117–286

Cardiomyopathy associated*

Q8N3K9

CMYA5

Cytoskeleton

4

3972–4069

Biglycan

P21810

BGN

Extracellular

2

191–368

Dynactin 1*

Q14203

DCTN1

Cytoskeleton

3

910–1144

Beta-enolase 3 (beta, muscle)*

P13929

ENO3

Cytoskeleton

7

85–434

Filamin C, gamma

Q14315

FLNC

Cytoskeleton

2

2608–2692

Myosin binding protein C, cardiac*

Q14896

MYBPC3

Cytoskeleton

11

945–1274

Myosin, heavy chain 6, cardiac muscle, alpha*

P13533

MYH6

Cytoskeleton

3

846–958

Myosin, heavy chain 7, cardiac muscle, beta*

A5YM51

MYH7

Cytoskeleton

14

1865–1935

Myomesin (M-protein) 2*

P54296

MYOM2

Cytoskeleton

6

1283–1465

Ryanodine receptor 2 (cardiac)

Q92736

RYR2

SR

3

1864–2359(4968)#

Titin-cap (telethonin)

O15273

TCAP

Cytoskeleton

6

92–167

Titin*

Q8WZ42

TTN

Cytoskeleton

5

1493–1890(5605)

Troponin I type 3*

Q6FGX2

TNNI3

Cytoskeleton

5

-17–210

WD repeat domain 1

O75083

WDR1

Cytoskeleton

3

221–466#

5

Fermentation/Respiration
Acetyl-CoA acyltransferase 2*

P42765

ACAA2

Mito IM

Aldehyde dehydrogenase, mitochondrial

P05091

ALDH2

Mito Matrix

208–397

Aldolase A, fructose-bisphosphate*

P04075

ALDOA

Cytoplasm

15

159–418
137–503

266–470#

ATP synthase subunit alpha, mitochondrial, F1*

P25705

ATP5A1

Mito IM/Matrix

11

Cytochrome P450, family 1, subfamily B, polypeptide1

Q16678

CYP1B1

ER

4

436–543

Enolase 1, alpha-enolase

P06733

ENO1

Cytoskeleton

4

-36–341#

Electron-transfer-ﬂavoprotein, alpha subunit*

P13804

ETFA

Mito Matrix

15

108–284

Glyceraldehyde 3-phosphate dehydro.*

P04406

GAPDH

Cytoplasm

19

21–293

Hydroxyacyl-CoA dehydro./3-ketoacyl-CoA thiolase*

P55084

HADHB

Mito IM/OM

5

205–452#

Methylcrotonoyl-CoA carboxylase beta chain

Q9HCC0

MCCC2

Mito Matrix

2

42–563

Malate dehydro. 1, NAD (soluble)

P40925

MDH1

Mito, Cytoplasm

2

68–352#

Cytochrome c oxidase subunit 1

P00395

MT-CO1

Mito IM

12

222–512

Cytochrome c oxidase subunit 2

P00403

MT-CO2

Mito IM

2

67–227

Cytochrome c oxidase subunit 3

P00414

MT-CO3

Mito IM

2

1–260

NADH dehydro. (ubiquinone) 1 alpha subcomplex 6*

P56556

NDUFA6

Mito IM

2

66–154

NADH dehydro. (ubiquinone) 1 alpha subcomplex, 13

Q9P0J0

NDUFA13

Mito IM

2

-5–144

Oxoglutarate (alpha-ketoglutarate) dehydro.*

A2VCT2

OGDH

Mito

2

907–1019

Phosphoglucomutase 1

P36871

PGM1

Cytoplasm

2

250–365#

Succinate dehydro. complex, subunit A*

D6RFM5

SDHA

Mito IM

5

351–654
(Continued)
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Table 2. (Continued)
Protein Name

UniProt Accession

Gene Symbol

Cellular Localization**

# hits

aa

AGAP11

Cytoplasm

2

19–550#

Signal Transduction
Ankyrin repeat & GTPase Arf activating protein 11

Q8TF27

DNA-damage-inducible transcript 4

Q9NX09

DDIT4

Cytoplasm

2

167–232

Dual speciﬁc phosphatase 1

P28562

DUSP1

Nucleus

2

158–367

Four and a half LIM domains 2*

Q14192

FHL2

Nucleus

10

47–279

Myozenin 2

Q9NPC6

MYOZ2

Cytoplasm

2

31–264#

Parvin, alpha

Q9NVD7

PARVA

PM

2

181–412

Prosaposin*

Q5BJH1

PSAP

Lysosome

14

425–526

Zinc ﬁnger protein 335*

Q8IW09

ZNF335

Nucleus

2

610–1342#

Gene/Protein Expression
Brain expressed X-linked 4

Q9NWD9

BEX4

Cytoplasm

2

1–120

Eukaryotic translation elongation factor 1 alpha 1*

P68104

EEF1A1

Ribosome, Nucleus

13

213–462#

Eukaryotic translation elongation factor 2

Q6PK56

EEF2

Ribosome

2

685–858

Eukaryotic translation initiation factor 4A2

Q14240

EIF4A2

Ribosome

3

360–407

Glycine-tRNA synthetase

P41250

GARS

Cytoplasm

2

254–739#

Asparagine-tRNA ligase

O43776

NARS

Cytoplasm

2

379–548

NHP2 non-histone chromosome protein 2-like 1

P55769

NHP2L1

Nucleus

2

41–123#

Ribosomal protein L11, 60S*

P62913

RPL11

Ribosome

10

83–177

Ribosomal protein L36a, 60S*

J3KQN4

RPL36A

Ribosome

13

81–142

Ribosomal protein L36a-like, 60S

Q969Q0

RPL36AL

Ribosome

2

45–106

Ribosomal protein S11, 40S

P62280

RPS11

Ribosome

4

90–158

THUMP domain-containing 2

Q9BTF0

THUMPD2

Cytoplasm

2

11–503#

ATP-binding cassette, sub-family C, member 9

O60706

ABCC9

PM

2

1263–1549#

Transport
ATP-binding cassette, sub-family D, member 4

O14678

ABCD4

Peroxisome

2

204–606

ATPase, H+ transporting, V1 subunit E1

Q53Y06

ATP6V1E1

Lysosome

2

165–196#

Myoglobin

P02144

MB

Cytoplasm

3

9–154

Protein phosphatase, IK

Q8N3J5

PPM1K

Mito Matrix

2

260–372

Stromal cell-derived factor 2

Q99470

SDF2

Extracellular

2

(-9)–211

Solute carrier family 2, member 1

P11166

SLC2A1

PM

3

369–492

A2M

Extracellular

3

1184–1474#

Protein Degradation
Alpha-2-macroglobulin

P01023

Cathepsin B

P07858

CTSB

Lysosome

4

238–339

Cathepsin D*

P07339

CTSD

Lysosome

4

229–413

Nucleotide Metabolism
Creatine kinase, muscle

P06732

CKM

Cytoplasm

3

133–381#

Guanylate kinase 1*

Q96IN2

GUK1

Cytoplasm

3

11–197

Putative deoxyribonuclease 1

Q6P1N9

TATDN1

Nucleus

2

-6–298#

Beta-2-microglobulin*

P61769

B2M

Extracellular

8

-11–119

Complement component 1, q subcomponent, A chain

P02745

C1QA

Extracellular

2

134–245

Thymocyte selection associated family member 2

Q5TEJ8

THEMIS2

Cytoplasm

2

246–447

Immune

Cell Adhesion
Lectin, galactoside-binding, soluble, 1 (Galectin-1)*

P09382

LGALS1

Extracellular

9

-22–135

Plakophilin 2

Q99959

PKP2

Cytoskeleton’PM

3

619–837

PM

2

101–303

Osmoregulation
ATPase, Na+/K+ transporting, beta 1

Q6LEU2

ATP1B1

(Continued)
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Table 2. (Continued)
Protein Name

UniProt Accession

Gene Symbol

Cellular Localization**

# hits

aa

Lysosome

2

290–389

Cytoplasm

6

175–391

Small Molecule Biosynthesis
N-acylsphingosine amidohydrolase 1

Q13510

ASAH1

Oxidoreductive Stress
Thioredoxin-interacting protein

Q9H3M7

TXNIP

Chaperone
Heat Shock Protein 2 (HspB2)

Q16082

HSPB2

Cytoplasm

6

-66–175

Crystallin, alpha B*

P02511

HSPB5

Cytoskeleton

34

-3–175

Unknown
Dynactin 6

O00399

DCTN6

Mito

3

82–190

Myeloid leukemia factor 2

Q15773

MLF2

Nucleus

2

98–248#

Nucleotidase domain containing 2

Q9H857

NT5DC2

unknown

2

302–462

* Indicates the 30 proteins shown to be HspB2 dependent in the Y2H binding assay. All others were not tested for dependency. Of the total 49 plasmids
tested for dependency from the multi-hitter list, 10 did not appear in frame from sequence analysis, 81.6% showed a positive Y2H result that was
dependent on HspB2 (indicating a HspB2/prey interaction), 10.2% were false positives (they grew with either HspB2 or the empty bait plasmid), and 8.2%
were true negatives (they did not grow with either HspB2 or the empty bait). Out of frame fusions, false positives and true negatives revealed through this
analysis are not listed.
** Abbreviations include Endoplasmic Reticulum (ER), Mitochondrial (Mito), Mitochondrial Inner Membrane (Mito IM), Mitochondrial Outer Membrane
(Mito OM), Mitochondrial Matrix (Mito Matrix), Plasma Membrane (PM) and Sarcoplasmic Reticulum (SR).]
Indicates that the ﬁnal amino acid listed is the C-terminal amino acid of the native protein.
Indicates that there is extra DNA from the mitochondrial chromosome on the 3’ end of this construct in addition to the MYH6 DNA which adds an extra 82
aa.
# Indicates that the sequence quality was too poor to unambiguously tell the N-terminal fusion (WDR1, NHP2L, ATP6V1E1, TATDN1, MLF2) or the Cterminal end (RYR2, WDR1, ALDH2, ENO1, HADHB, MDH1, PGM1, AGAP11, MYOZ2, ANF335, GARS, CKM, ABCC9, EEF1A1, THUMPD2, A2M).
doi:10.1371/journal.pone.0133994.t002

The Y2H screen identifies mitochondrial clients for HspB2
The 84 high confidence binding partners identified by Y2H were further analyzed for their cellular localization and molecular functions. The majority of the binding partners have been
reported to primarily localize to the mitochondria (19%), the cytoskeleton (24%) and the cytoplasm (19%) (Fig 4B). The functional classes to which the most interacting partners belong are
those of fermentation/respiration (23%, including 13 targets directly involved in oxidative
phosphorylation) and myofibril or cytoskeletal function (23%), consistent with the previously
reported roles of HspB2 in ATP production [6, 9, 13] and muscle fiber maintenance [4, 6, 26,
29, 36, 37]. The high proportion of mitochondrial proteins identified by Y2H may, in part, be
due to the abundance of mitochondria in cardiac tissue, yet there is interest in this subset of
mitochondrial proteins when considering the total mitochondrial proteome, with over 1,000
mitochondrial proteins estimated in studies of both human [38] and rat [14] cardiac tissues.

Coaffinity proteomics of HspB2 validates mitochondrial targets of HspB2
The identification of multiple mitochondrial binding partners poses a novel hypothesis that
HspB2, a resident cytosolic molecular chaperone, might also have distinct mitochondrial clientele. Such clientele would be consistent with the transient association with the outer mitochondrial membrane reported by Nakagawa et al. from tissue culture studies [8]. To test this
hypothesis, co-purification studies were performed followed by quantitative mass spectroscopy
to identify both HspB2 mitochondrial localization as well as native mitochondrial binding partners [39, 40]. Anti-HspB2 antibodies [9] were used to IP protein from cardiac muscle
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Fig 4. A large-scale HspB2 yeast two-hybrid (Y2H) screen reveals specificity in sHSP binding partners and identifies putative myofibril and
mitochondrial clientele. (A) Y2H assays for direct binding between HspB2 or HspB5 baits and four putative HspB2 binding partner preys reveals nonredundant binding. Y2H prey plasmids (pGADT7, Clontech) retrieved from the HspB2 Y2H screen were transformed into Y2HGold cells (Clontech)
containing bait plasmids (pGBKT7, Clontech) with either HSPB2 (pHSPB2-BD) or HSPB5 (pHSPB5-BD) fused to the Gal4 DNA binding domain (BD), or the
empty vector (pEV-BD). Overnight cultures were grown for 48 h in SD-Trp-Leu to select for plasmids, then serially diluted 1:5 and plated on SD-Trp-Leu-HisAde plates to select for protein-protein interaction. These four (ATP synthase alpha subunit (ATP5A1), alphaB-crystallin (HspB5), ribosomal protein L11
(RPL11), and zinc finger protein 335 (ZNF335) are representative. Results of all 12 binding partners are given in Table 3. (B) Pie charts summarizing the
reported localization of the putative HspB2 binding partners revealed that a majority are localized to the cytoplasm, cytoskeleton or mitochondria. (C) Pie
charts summarizing the reported function for putative cardiac HspB2 binding partners reveals two major categories of myofibril or mitochondrial function.
Function and localization was assigned by basic description on GeneCards [73], UniProt [73, 74] or literature searches when necessary.
doi:10.1371/journal.pone.0133994.g004

mitochondrial lysate derived from either the HSPB2NTg control, heart-specific transgenic
(HSPB2cTg), or heart-specific KO (HSPB2cKO) mice. Co-purified proteins were run on
SDS-PAGE for fractionation and then identified by quantitative LC/MS/MS in two technical
replicates. HspB2 was identified in the HSPB2cTg samples confirming mitochondrial association, but it was not identified either in the samples from littermate control (HSPB2NTg) or
HSPB2cKO mice, presumably due to low or no HSPB2 expression, respectively. This restricted
detection of HspB2 in only the OE lysates is consistent with previous assays for mitochondrial
association of HspB2 and is thought to be due to low HspB2 expression [9].
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Table 3. HspB2 is highly specific for its targets as revealed by a comparison of HspB2 and HspB5
binding partners. Twelve binding partners from the HspB2 Y2H screen were tested for their ability to bind
HspB2 or HspB5. The columns are as follows: gene (the name of the gene encoded on the library ‘prey’ plasmid retrieved from the Y2H screen), plasmid (the pJG number of the purified plasmid), HspB2 (the Y2H protein-protein interaction result using HspB2 as bait), HspB5 (the Y2H protein-protein interaction result using
HspB5 as bait), and EV (the Y2H result using an empty vector control). Strong, medium or weak indicates
apparent strength of the interaction as determined by growth on selective media (SD–Trp–Leu–His–Ade); NG
means no detectable growth. HspB5 was used as a positive control and was also retrieved from the yeast
two-hybrid screen.
Gene

Plasmid

HspB2

HspB5

EV

HSPB5

pJG933

Strong

Strong

NG

ALDOA

pJG774

Strong

Weak

NG

ATP5A1

pJG745

Strong

NG

NG

DCTN1

pJG885

Strong

Weak

NG

ENO3

pJG877

Strong

NG

NG

EEF1A1

pJG882

Strong

NG

NG

MYH6

pJG785

Strong

NG

NG

OGDH

pJG988

Strong

NG

NG

PSAP

pJG878

Strong

Strong

NG

RPL11

pJG903

Strong

NG

NG

SDHA

pJG871

Strong

NG

NG

ZNF335

pJG944

Strong

NG

NG

doi:10.1371/journal.pone.0133994.t003

A total of 68 proteins (Table 4) were uniquely identified in the HSPB2cTg samples (Fig 5A).
An additional 127 proteins were identified in both the HSPB2cTg and HSPB2cKO samples,
suggesting they bind nonspecifically to the resins used in purification. The 68 HSPB2cTg-specific proteins compared with 12 HSPB2cKO-specific suggest HspB2-specific binding. In addition, the 68 HSPB2cTg-specific proteins were enriched for membrane bound proteins involved
in oxidative phosphorylation, transport and metabolism (65%, Fig 5B), consistent with the
Y2H results.
When combined, the 84 high confidence targets from the Y2H screen and 68 from co-IP
studies identify 149 unique proteins as putative HspB2 clientele. Three proteins were identified
by both methods (HspB2, OGDH, and MCCC2). The low level of overlap between the two
independent screens is due to the difference in using whole-cell verses mitochondrial extract
and is also consistent with previous reports on differences due to the diverse strengths of each
approach [41]. Of note, if all of the proteins identified in the HSPB2cTg co-IP samples are analyzed (including the 127 that also occur in the HSPB2cKO control), there are 39 proteins that
overlap between the Y2H and co-IP samples. These additional proteins interacted with the
purification resin itself and may represent proteins that naturally aggregate easily, prime targets
for chaperones. This aggregation, however, makes it difficult to show protein-protein association by co-IP and these proteins are not included in the 68 retrieved from co-IP.

Network analysis of the combined HspB2 cardiac interactome reveals
functional links to myopathies and neurodegenerative disease
HspB2 is one of only a few sHSP to date (including HspB9 and HspB10) without identified disease-associated human alleles. Therefore, the combined high confidence Y2H and co-IP interactome (a total of 149 unique proteins) was analyzed for diseases associated with the putative
HspB2 binding partners. There were 35 Y2H and 14 co-IP HspB2 binding partners associated
with disease, and of these, 28 (57%) were associated with myopathies and neurodegenerative
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Table 4. Unique proteins identified from HSPB2 co-immunoprecipitation from HSPB2cTg heart tissue when compared to the HSPB2cKO heart tissue. This table lists information on all 68 uniquely identified proteins from the HSPB2cTg samples when compared with those identified from the HSPB2cKO
samples by quantitative mass spectroscopy. It contains the following information sequentially: protein name, UniProt [73, 74] protein accession number,
gene name, primary cellular localization from HPRD [76] or UniProt, molecular weight (MW), and protein length (# of amino acids). The proteins are functionally categorized by their description on UniProt and/or GeneCards.
Protein Name

UniProt
Accession

Gene
Symbol

Cellular
Localization**

MW

Protein Length
[67]

373

Fermentation/Respiration
Protein Acad12

D3Z2B3

ACAD12

Mito

41332

ATP synthase subunit e, mitochondrial

P56385

ATP5I

Mito IM

8218

71

ATP synthase subunit g, mitochondrial

O75964

ATP5L

Mito IM

11407

103

CDGSH iron-sulfur domain-containing protein 1

Q9NZ45

CISD1

Mito OM

12079

108

Carnitine O-palmitoyltransferase 1, muscle isoform

A5PLL0

CPT1B

Mito,OM

88202

772

Carnitine palmitoyltransferase 2

P23786

CPT2

Mito IM

24889

223

Carnitine O-acetyltransferase

P43155

CRAT

Mito IM, ER, Perox

70823

626

Cytochrome c oxidase subunit 7A-related protein

Q6FGA0

COX7A2L

Mito IM

14913

134

Dihydrolipoyl dehydrogenase, mitochondrial

P09622

DLD

Mito Matrix

54254

509

Dihydrolipoyllysine-residue succinyltransferase

Q6IBS5

DLST

Mito, Nucleus

22212

454

Methylcrotonoyl-Coenzyme A carboxylase 2 (Beta)

Q9HCC0

MCCC2

Mito

61362

563

Novel protein GN = Mtfp1

Q9UDX5

MTFP1

Mito

18314

166

NADH-ubiquinone oxidoreductase chain 1

P03886

MT-ND1

Mito IM

36012

318

NADH-ubiquinone oxidoreductase chain 4

P03905

MT-ND4

Mito IM

51869

459

NADH-ubiquinone oxidoreductase chain 5

P03915

MT-ND5

Mito IM

68441

607

NADH dehydrogenase 1 alpha subcomplex subunit 11

Q86Y39

NDUFA11

Mito IM

14965

141

NADH dehydrogenase 1 beta subcomplex subunit 3

O43676

NDUFB3

Mito IM

11674

104

NADH dehydrogenase 1 beta subcomplex, 5

O43674

NDUFB5

Mito IM

14038

119

NADH dehydrogenase 1 beta subcomplex, 6

O95139

NDUFB6

Mito IM

15498

128

NADH dehydrogenase 1 beta subcomplex subunit 8

O95169

NDUFB8

Mito IM

21858

186

NADH dehydrogenase 1 beta subcomplex subunit 9

Q9Y6M9

NDUFB9

Mito IM

21966

179

NADH dehydrogenase 1 beta subcomplex, 11

Q9NX14

NDUFB11

Mito

17426

151

NADH dehydrogenase 1 subunit C2

O95298

NDUFC2

Mito IM

14146

120

NAD(P) transhydrogenase, mitochondrial

Q13423

NNT

Mito IM

113823

1086

2-oxoglutarate dehydrogenase, mitochondrial

Q02218

OGDH

Mito

117741

214

Ubiquinol-cytochrome c reductase hinge protein

P07919

UQCRH

Mito IM

10417

89

Cytochrome b-c1 complex subunit 8

O14949

UQCRQ

Mito IM

9751

82

Platelet glycoprotein 4

P16671

CD36

Golgi, PM

52681

472

Mitochondrial carrier homolog 2

Q9Y6C9

MTCH2

Mito IM

32328

294

Metaxin 2

O75431

MTX2

Mito OM

29740

263

ADP/ATP translocase 2

Q6NVC0

SLC25A5

Mito IM

32915

298

Calcium-binding mitochondrial carrier protein Aralar1

O75746

SLC25A12

Mito IM

74554

677

Mitochondrial carnitine/acylcarnitine carrier protein

O43772

SLC25A20

Mito IM

33010

301

Solute carrier family 25 member 42

Q86VD7

SLC25A42

Mito IM

35241

318

Perlecan (Heparan sulfate proteoglycan 2)

Q2VPA1

HSPG2

Extracellular

469023

4735

Laminin subunit alpha-2

P24043

LAMA2

Extracellular

342761

3105

Laminin subunit gamma-1

P11047

LAMC1

Extracellular

177298

1607

Nidogen-1

P14543

NID1

Extracellular

136519

1245

Vinculin

P18206

VCL

Cytoplasm

116717

1066

Transport

Cell Adhesion

Small Molecule Biosynthesis and Catabolism
(Continued)
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Table 4. (Continued)
Protein Name

UniProt
Accession

Gene
Symbol

Cellular
Localization**

MW

Protein Length
[67]

Apolipoprotein O

Q9BUR5

APOO

Ferrochelatase (EC 4.99.1.1)

P22830

FECH

Mito

22587

198

Mito, IM

44667

Amine oxidase [ﬂavin-containing] B

P27338

MAOB

Mito OM

399

58541

520

Methylcrotonoyl-CoA carboxylase subunit alpha

Q96RQ3

MCCC1

Mito IM/Matrix

79327

717

Isoform 2 of Perilipin-4

Q96Q06

PLIN4

Cytoplasm,PM

139415

1403
208

Gene/Protein Expression
Crip2 protein

P52943

CRIP2

Nucleus,Cortex

22709

Methylglutaconyl-CoA hydratase, mitochondrial

Q13825

AUH

Mito

22898

219

39S ribosomal protein L12, mitochondrial

P52815

MRPL12

Mito

21691

201

Nascent polypeptide-associated complex subunit alpha

Q13765

NACA

Cytoplasm,Nucleus

220499

2187

Sorting and assembly machinery component 50 homolog

Q9Y512

SAMM50

Mito, OM

51847

469

Myoﬁbril or Cytoskeleton Structure/Regulation
Alpha actinin 1a

P12814

ACTN1

Cytoplasm, Z-disk

102706

887

Spectrin alpha 2

A3KGU5

SPNA2

Cytoskeleton

282895

2457

Isoform 2 of Spectrin beta chain, brain 1

Q62261

SPNB2

Cytoskeleton

274223

2363

Troponin C, slow skeletal and cardiac muscles

P63316

TNNC1

Cytoskeleton

18421

161

Uncharacterized protein GN = Vim

P08670

VIM

PM

52185

453

Intracellular Trafﬁcking
AP-3 complex subunit delta-1

O14617

AP3D1

Cytoplasm,PM

135081

1199

EH-domain containing 4

Q9H223

EHD4

ER,PM

61481

541

Ras-related protein Rab-7a

P51149

RAB7A

Lysosome

23472

207

Chaperone
Heat shock cognate 71 kDa protein

Q96IS6

HSPA8

Cytoplasm

70871

646

Heat shock protein beta-2

Q16082

HSPB2

Cytoplasm

20357

182

Dynamin-like 120 kDa protein, mitochondrial

O60313

OPA1

Mito IM

78918

692

Complement component 1 Q subcomponent-binding
protein

Q07021

C1QBP

Mito Matrix

31013

278

AIFM1

Mito IM/OM

66748

612
265

Cell Death
Immune

Oxidoreductive Stress
Apoptosis-inducing factor, mitochondrion-associated 1

O95831
Unknown

Apolipoprotein O-like

Q6UXV4

APOOL

Mito IM

29244

Mitochondrial pyruvate carrier

Q9D023

MPC2

Mito IM

14269

127

ES1 protein homolog, mitochondrial

Q9D172

D10JHU81E

Mito

28072

266

Uncharacterized protein GN = Ogdhl

Q9ULD0

OGDHL

Cytoplasm

116584

1029

Prohibitin

P35232

PHB

Mito IM

29803

272

Translocase of inner mitochondrial membrane domain
containing 1

Q9NPL8

TIMMDC1

Mito IM

31774

285

**Abbreviations include Endoplasmic Reticulum (ER), Mitochondrial (Mito), Mitochondrial Inner Membrane (Mito IM), Mitochondrial Outer Membrane (Mito
OM), Mitochondrial Matrix (Mito Matrix), Peroxisome (Perox), Plasma Membrane (PM)
doi:10.1371/journal.pone.0133994.t004

diseases such as Alzheimer’s disease (AD) (Fig 5C). These results predict that alterations in
HspB2 function may contribute to these diseases.
Although the high confidence Y2H and co-IP HspB2 interactome revealed proteins with a
wide range of biological functions, it was apparent that many of these proteins overlap in their
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Fig 5. Co-purification of mitochondrial HspB2 binding partners supports the mitochondrial role predicted by Y2H and mouse data and identifies
associations with disease. (A) Analysis of 207 proteins retrieved via co-immunoprecipitation (IP) from mouse cardiac mitochondria lysate with anti-HSPB2
antibodies reveals 68 proteins unique to the HSPB2cTg samples, 12 unique to the HSPB2cKO control and 127 that overlap. Mitochondrial HspB2 was
immunopurified from mice harboring either transgenic cardiac HSPB2 (HSPB2cTg) or an HSPB2 cardiac knockout (HSPB2cKO). In each group,
mitochondria were combined from four mouse hearts, lysed in 0.1% NP-40 homogenization buffer and 2 mg was incubated with anti-HspB2 antibodies. The
IP eluates were then fractionated on SDS-PAGE, excised and analyzed by LC-MS/MS. Samples had one biological replicate and two technical replicates.
(B) The unique proteins retrieved only from HSPB2cTg tissue (68 total) are enriched in oxidative phosphorylation functions. Predicted protein function was
inferred by Gene Ontology [75]. (C) Diseases associated with proteins in the combined HspB2 Y2H and IP interactomes predict a role for HspB2 in
neurodegenerative diseases and myopathies. Of the 149 HspB2 binding partners, 49 are associated with diseases and 57% of these are associated with
myopathies and neurodegenerative diseases including cardiomyopathy and Alzheimer’s disease. Associated diseases were identified by the Online
Mendelian Inheritance in Man (OMIM) database (McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD). World Wide
Web URL: http://omim.org/).
doi:10.1371/journal.pone.0133994.g005

biological pathways. In order to identify key pathways influenced by HspB2, the combined
Y2H and co-IP interactome (149 proteins) was analyzed using protein-protein interaction and
functional annotation datasets in Cytoscape [42]. Detailed analysis of the interactome using
Cytoscape revealed a large network with 69 of the interactome proteins having 365 reported
protein-protein interactions (Fig 6). The remaining 80 proteins not included in this larger network have one or zero known binding partners. There are two major clusters of this large network, one that contains primarily myofibril proteins and the other primarily fermentation/
respiration proteins, consistent with the functional analysis of these targets (Figs 4C and 5B).
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Amid the 64 mitochondria-associated protein partners of HspB2 (19 from Y2H, 48 from co-IP
and 3 that overlap), 32 (50%) are in this large Cytoscape network, with 200 of the 365 total
interactions (55%) reported occurring with these 32 mitochondria-associated proteins. The
fact that many (50%) of the mitochondrial proteins from both screens are previously reported
binding partners suggests that HspB2 is targeting related proteins or specific pathways.
Gyceraldehyde 3-phosphate dehydrogenase (GAPDH) is a central protein in the network
(indicated in orange) with many connections to the major protein cluster with myofibril functions. GAPDH catalyzes the sixth step of glycolysis and is a key metabolic switch for partitioning glucose to TCA for respiration [43], and has recently been implicated in a wide variety of
pathways including mitochondrial functions (for recent reviews see [44–48]). The pivotal position of GAPDH within the cluster and its connection to mitochondrial function suggested
GAPDH as an important HspB2 target central to these pathways, and it was investigated
further.

HspB2 protects GAPDH from heat inactivation
GAPDH was chosen to validate by further characterization because it was a central node in the
bioinformatic analysis of the HspB2 interactome, it is a soluble protein (facilitating its characterization as chaperone target), and it has been associated with all of the HspB2-related cardiac
phenotypes including maintaining ATP levels (Fig 3 and [9]), mitochondrial outer membrane
potential ([31, 32]) and protection from I/R-induced infarction (Fig 2, Table 1). Specifically,
GAPDH has recently shown to maintain cellular ATP levels during mitochondrial crisis [49],
and to localize to mitochondria where it regulates respiratory complex I cytochrome C-oxidase
[49], mitochondrial outer membrane permeability (MOMP) [50] and mitochondrial-based
apoptosis [50, 51] in cardiomyocytes. These roles for GAPDH in MOMP and apoptosis have
also been established in other tissues and cell lines [52–55]. In addition, GAPDH enhances
aggregation and cytotoxicity in models of Huntington and Amytrophic Lateral Sclerosis [43,
56] as well as Alzheimer’s disease [57–59].
We tested directly the ability of HspB2 to prevent heat-induced aggregation of GAPDH
through in vivo and in vitro chaperone assays (Fig 7). To assess the effects of HspB2 on
GAPDH in vivo, GAPDH expression in cardiac protein lysates from HSPB2cTg mice was compared with the littermate controls (HSPB2NTg). No significant differences in soluble GAPDH
were observed when compared with β-Tubulin and GAPDH was not observed in the pellet of
homogenized mouse cardiac tissue (Fig 7A and 7B). These results suggest that HspB2 may
only be important for GAPDH solubility or folding during stress states. To test this hypothesis,
the effects of HspB2 expression on GAPDH heat aggregation were investigated in mammalian
cells. In C2C12 cells, HspB2 was overexpressed prior to heat stress (30 m at 45°C) and cell
lysates examined for levels of GAPDH contained in the supernatant and pellet fractions. When
compared with control cells, forced HspB2 expression significantly prevented aggregation and
increased solubilized GAPDH protein (~92% vs 62%, P< 0.005), whereas just over one-third
(38%) aggregated, rescuing 30% of the total GAPDH protein (Fig 7C and 7D). In contrast,
HspB2 did not recognize β-Tubulin as a binding partner in either the Y2H or co-IP interactomes; accordingly, HspB2 did not confer protection of β-Tubulin when used as a control
under these conditions. These results offer for the first time evidence for HspB2-dependent stabilization of GAPDH, a key protein in the regulation of ATP levels and apoptosis.
In addition to in vivo assays, the ability of HspB2 to prevent GAPDH aggregation was investigated in vitro. HspB2 was able to prevent in vitro aggregation of almost three quarters (~73%)
of the GAPDH where ~50% of GAPDH aggregated without HSPB2 (increasing solubility by
about half, Fig 7E and 7F). However, HspB2 also prevented aggregation of other proteins tested
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Fig 6. Analysis of the HspB2 interactome confirms the related nature of the binding partners and identified two major networks involved in
mitochondrial metabolism and myofibril maintenance. Analysis of known protein-protein interactions among the 149 HspB2 binding partners reveals a
tight network of 69 proteins. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (indicated by orange coloring) is investigated further in this study.
Cytoscape version 3.2.1 [19] was used to construct each of the protein-protein interaction networks by retrieving previously identified interactions from the
mentha, Reactome-Fls, Reactome, IntAct and MINT databases (partners reported for either human or mouse proteins) and mapping them into a single
merged network.
doi:10.1371/journal.pone.0133994.g006

that were not identified in this study, including citrate synthase (CS). Citrate synthase was
reported as a weak client, with HspB2 providing only partial protection in a previous study
[21], however these results suggest non-specificity of HspB2 binding in vitro with HspB2 rescuing both heat denatured GAPDH and CS.

Discussion
The physiological importance of the family of sHSPs in human disease has been well established, however the unique roles of the ten members are just beginning to be unveiled due to
the complexity of overlapping function [1, 2, 60]. This study utilized the power of OE to reveal
cardiac HspB2-associated phenotypes that are not seen with gene KO, most likely due to overlapping sHSP function. In addition, a system’s biology approach was taken to identify specific
molecular functions of HspB2 via a cardiac HspB2 interactome, which supports the observed
phenotypes and provides key targets for future investigation.
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Fig 7. HspB2 protects glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from heat stress. (A) Overexpression of HspB2 does not alter GAPDH
levels in mouse cardiac lysates. Total protein concentration was determined and western blots were performed using anti-GAPDH with anti-beta Tubulin and
anti-histone3 as loading controls as previously described [9]. (B) Quantification of A using ImageJ software [22]. (C) Overexpression of HspB2 protects
GADPH from denaturation in mammalian C2C12 cells subjected to heat shock. Plasmids bearing human HspB2 fused to myc or the empty plasmid control
(pCMV-myc) were transfected into C2C12 cells in a 6-well plate using 6.5-μl lipofectamine 2000 (Life Technologies) and manufacturers protocol. After 48 h at
37°C, cells were shifted to 45°C for 30 m and then placed back at 37°C for 3 h prior to lysis. Debris was pelleted at 13,000 rpm for 5 m, and pellet (P) and
supernatant (S) were resuspended in 1X SDS buffer. Samples were boiled 2 m, analyzed by SDS-PAGE and transferred to nitrocellulose paper for
visualization using anti-GAPDH antibody, anti-beta Tubulin antibody, and anti-Myc antibody (all antibodies are from Cell Signaling Technologies). (D) Protein
bands from C were quantified using ImageJ software [22]. (E) In vitro chaperone assay reveals HspB2-dependent protection of GAPDH aggregation,
however HspB2 appears to be non-specific in vitro. GAPDH or citrate synthase (control) was incubated with or without HspB2 at 37°C and 43°C and
aggregated protein was pelleted by centrifugation. Pellets (P) and supernatants (S) were assayed for protein by SDS-PAGE analysis (E) and quantified (F).
Briefly, 0.015 mM GAPDH or citrate synthase was incubated at 37°C or 43°C with or without 0.105 mM HspB2 in 40 mM HEPES-KOH buffer (pH 7.5).
Aggregates were then pelleted by centrifugation (13,000 rpm for 10 m in a microcentrifuge), run on SDS-PAGE, quantified using ImageJ software [22] and
normalized to the no HspB2 pellet to supernatant ratio for each run. Samples were run in triplicate. * P<0.05 when compared with corresponding control
group.
doi:10.1371/journal.pone.0133994.g007

The HspB2 protein was overexpressed in cardiac tissue (HSPB2cTg) where it reduced I/R
stress-induced infarct size (Fig 2A and 2B). In support of this finding, the HSPB2cTg animals
also had a lower troponin-1 level post surgery (Fig 2C) and were resistant to wall motion
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abnormality as observed at 24-hour time points post I/R (Table 1). These findings demonstrate
the power of OE in the study of complex, overlapping functions, as no difference in infarct size
was seen between the wild type (HSPB2wt) and HSPB2cKO mice, which may be due to functional overlap of HSPs. This study of cardiac OE also confirmed the HSPB2-dependent preservation of cellular ATP levels seen in the study of HSPB2cKO mice [9], with ATP content
following reperfusion significantly greater in the HSPB2cTg mice when compared to the control (Fig 3). These results mimic the function of putative HspB2 activators and suggest them as
cardioprotectant agents. In addition, they suggest a mitochondrial role for HspB2 that may
explain the protection of cardiac muscle from I/R stress, however a lack of reported mitochondrial HspB2 clientele prohibited molecular analysis.
Complex cellular protein networks underlie most genotype/phenotype relationships, making detailed analysis of protein interactomes essential in functional analysis, particularly with a
protein chaperone [61]. Two widely used strategies were employed for determining the HspB2
cardiac interacome; namely, large-scale Y2H screens and co-IP studies. The large-scale cardiac
Y2H screen retrieved 84 high confidence in vivo binding partners, whereas only four prior
HspB2 clientele binding partners were reported to date (DMPK [4], insulin, alcohol dehydrogenase and α-synuclein [21]). Interactions with three other sHSPs (HspB3 [25, 26], HspB5
[27] and HspB8 [28]) have also been previously reported, however, we only retrieved HspB5
from the screen. This may be due to low levels of HspB3 or HspB8 constructs in the Y2H
library, or nonfunctional Y2H fusion constructs. The later is highly probable as we were unable
to detect an interaction between HspB3 and HspB2 when HspB3 was cloned directly into the
Y2H prey (data not shown). The screen would also fail to uncover HspB2 targets that result
only from formation of sHSP heterocomplexes (such as an HspB2/HspB5 complex) because
only HspB2 was expressed in yeast.
The 84 HspB2 binding partners identified by Y2H are supported by the fact that the HspB2
bait interacted with less than 0.05% of the cardiac cDNA library and was specific for HspB2
when compared to other sHSPs. The HspB2 interactome was compared to the recently published HspB1 (Hsp27) Y2H interactome of 228 binding partners [35], and only two partners
were in common (EIF4A2 and GARS). Specificity was also supported by a comparison of
HspB2 and HspB5 binding where ten of 12 HspB2 binding partners tested preferentially interacted with HspB2 (see Table 3 and Fig 4A). HspB5 and HspB2, having 43% amino acid identity, are ohnologous [62] proteins in that they are divergently transcribed on human
chromosome 11 and appear to have arisen by gene duplication [63]. Differences in function
have been attributed to differences in their expression levels and tissue-type patterns, however,
the non-redundant clientele-specificity reported herein suggests differential function and supports the unique structure reported for HspB2 when compared with HspB5 [21] as well as the
non-redundant cardiac phenotypes [9].
In order to identify key pathways of HspB2 function from among the binding partners, a
systems biology approach was used to map previously known protein-protein interactions,
protein localization patterns, and related diseases. Such approaches have proven fruitful in
identifying key pathways involved in protein function as well as human disease [61]. Functional analysis of the 84 Y2H binding partners revealed an abundance of proteins involved in
myofibril and mitochondrial function (Fig 4C). Small HSPs have long been known for stabilizing myofibril structure in both skeletal and cardiac sarcomeres and HspB2 is no exception [6,
36], however this is the first report of putative mitochondrial clientele for HspB2.
The abundance of putative mitochondrial clientele posit HspB2 as a key factor in maintaining cardiac mitochondrial function, particularly when combined with the increased ability to
maintain ATP seen in the HSPB2cTg mice (Fig 3). Several of the mitochondrial proteins are
reported to localize to the inner membrane and matrix (Table 2) while HspB2 has been
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associated with the outer mitochondrial membrane, therefore, HspB2 may function as a chaperone for these proteins by helping refold exported, denatured proteins during stress or it may
be involved in the import and folding of naïve proteins. In support of a mitochondrial role for
HspB2, HspB2 and/or HspB5 have recently been shown to regulate ROS generation and respiration [64]. Cardiac muscle has evolved to be highly resistant to fatigue due to the high proportion of mitochondria within each cardiomyocyte, which is estimated at 40% weight compared
with 2% in skeletal muscle [65]. Unlike other muscle, cardiac muscle is almost completely
dependent on oxygen with only 1% of energy being derived from anaerobic respiration. Mitochondrial damage is prevalent under growth conditions that stimulate high respiration, making
protein chaperones of utmost importance in the heart. We, therefore, set out to validate mitochondrial clientele for HspB2 through co-IP.
The mitochondrial HspB2 clientele obtained by Y2H were supported by 68 proteins
retrieved from co-IP with cardiac, mitochondrial HspB2 (Fig 5), with three proteins identified
by both methods (HspB2, OGDH, and MCCC2). The low level of overlap between the two
independent screens is consistent with previous reports and is due to the differences in wholecell verses mitochondrial extract as well as the diverse strengths of each approach; co-IP is
likely to retrieve large protein complexes while the Y2H primarily identifies direct protein
interactions occurring in non-mammalian cells [41]. Although we have only been able to detect
HspB2 in mitochondrial fractions when overexpressed in both this study and our previous
study [9], HspB2 has also been shown to localize to the mitochondrial membrane in tissue culture studies [8]. This inability to detect HspB2 in mitochondrial fractions under normal cellular
conditions has been attributed to its low level of de novo expression as well as its loose association with the mitochondria [9]. The precise role of HspB2 remains to be determined, but the
combined phenotypic and interactome results herein strongly argue for a mitochondrial role
for HspB2 and identify 64 putative mitochondria-associated clientele to guide future study.
To test the in vivo significance of the interactome and analysis, GAPDH was studied in
more detail due to its identification as a central hub in the protein-protein interaction network
(Fig 6). In addition, GAPDH is soluble, which facilitates chaperone assays and has previously
reported roles in each of the HspB2-related phenotypes (namely maintenance of ATP levels
and reduced infarct size [49, 50, 52–55]). GAPDH was identified herein as a client through
chaperone assays (Fig 7), providing support for the interactome and analysis. Although multiple clienteles are likely to be involved in these phenotypes, GAPDH emerges as a key HspB2
target for further analysis due to its association with mitochondrial ATP production and
reduced infarct size.
Although many other sHSPs (including HspB5) have been found to play a role in various
diseases including neurodegenerative and muscular disease, disease-associated alleles of HspB2
have not been identified. The systems biology analysis herein, however, posits HspB2 as a
player in neurodegenerative, mitochondrial, and muscular disease (Fig 5C). In support of this
analysis, a dual KO of HSPB5 and HSPB2 was recently shown to enhance Alzheimer’s phenotypes when crossed with AD model mice, including the loss of synapses and the build-up of
amyloid beta-peptide (AB) plaques [66]. In addition, HspB2 has recently been found in the
senile plaques of AD [67]. This is not surprising given the recently discovered similarities
between proteotoxicity in cardiac dysfunction and in AD [68]. Both neurodegenerative and
muscular diseases have also been associated with mitochondrial dysfunction [48, 69, 70]. Since
the mitochondria of neuronal cells are the main organelle affected during AD [71, 72], mitochondrial dysfunction becomes a primary target for drug development. This analysis of the cardiac HspB2 interactome and cardiac HspB2 OE mice provides insight into the possible effects
of treatment with HspB2 activators, including protection from I/R stress and mitochondrial

PLOS ONE | DOI:10.1371/journal.pone.0133994 October 14, 2015

26 / 31

Cardiac Overexpression and Interactome of HspB2

maintenance. The results herein suggest these activators may not only be useful in cardioprotection, but in the treatment of neurodegenerative disease.

Supporting Information
S1 Fig. Mitochondrial permeability assays suggest protection by HspB2 overexpression,
however, the data is not statistically significant. Mitochondria were isolated from HSPB2
overexpressors (HSPB2cTg) or control hearts (HSPB2NTg), equilibrated for 5 m at room temperature and 250uM CaCl2 was loaded to induce swelling. Data was read at 540nm.
(TIF)
S1 Table. Putative HspB2 binding partners retrieved from the Y2H screen only once. Proteins retrieved a single time from a Y2H screen for HspB2 binding partners are given along
with the following information: protein name, UniProt [73] protein accession number (hyperlink), gene symbol, and cellular localization reported on UniProt, HPRD or GeneCards [73].
The proteins are functionally categorized by their description on UniProt and/or GeneCards.
See Table 2 for a complete list of putative HspB2 binding partners retrieved from the Y2H
screen multiple times.
(PDF)
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